You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMorphine
Accession NumberDB00295  (APRD00215)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionThe principal alkaloid in opium and the prototype opiate analgesic and narcotic. Morphine has widespread effects in the central nervous system and on smooth muscle. [PubChem]
Structure
Thumb
Synonyms
(-)-Morphine
(−)-morphine
(5alpha,6alpha)-17-Methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5alpha,6alpha)-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5R,6S,9R,13S,14R)-4,5-Epoxy-N-methyl-7-morphinen-3,6-diol
(7R,7AS,12bs)-3-methyl-2,3,4,4a,7,7a-hexahydro-1H-4,12-methano[1]benzofuro[3,2-e]isoquinoline-7,9-diol
Morfina
Morphia
Morphin
Morphine
Morphinum
Morphium
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AvinzaCapsule, extended release90 mg/1OralPfizer Laboratories Div Pfizer Inc2002-03-20Not applicableUs
AvinzaCapsule, extended release75 mg/1OralPfizer Laboratories Div Pfizer Inc2002-03-202015-11-30Us
AvinzaCapsule, extended release60 mg/1OralSTAT Rx USA LLC2002-03-20Not applicableUs
AvinzaCapsule, extended release90 mg/1OralLake Erie Medical DBA Quality Care Products LLC2011-10-25Not applicableUs
AvinzaCapsule, extended release30 mg/1Oralbryant ranch prepack2002-03-20Not applicableUs
AvinzaCapsule, extended release120 mg/1OralPfizer Laboratories Div Pfizer Inc2002-03-20Not applicableUs
AvinzaCapsule, extended release30 mg/1OralPfizer Laboratories Div Pfizer Inc2002-03-202015-12-29Us
AvinzaCapsule, extended release30 mg/1OralSTAT Rx USA LLC2002-03-20Not applicableUs
AvinzaCapsule, extended release90 mg/1Oralbryant ranch prepack2002-03-20Not applicableUs
AvinzaCapsule, extended release60 mg/1Oralbryant ranch prepack2002-03-20Not applicableUs
AvinzaCapsule, extended release90 mg/1OralSTAT Rx USA LLC2002-03-20Not applicableUs
AvinzaCapsule, extended release120 mg/1OralLake Erie Medical DBA Quality Care Products LLC2011-10-25Not applicableUs
AvinzaCapsule, extended release60 mg/1OralPfizer Laboratories Div Pfizer Inc2002-03-20Not applicableUs
AvinzaCapsule, extended release45 mg/1OralPfizer Laboratories Div Pfizer Inc2002-03-202015-11-30Us
AvinzaCapsule, coated, extended release60 mg/1OralLake Erie Medical DBA Quality Care Products LLC2011-10-25Not applicableUs
AvinzaCapsule, extended release120 mg/1Oralbryant ranch prepack2002-03-20Not applicableUs
Bar-morphine SRTablet, extended release100 mgOralBard Pharmaceuticals (1990) IncNot applicableNot applicableCanada
Bar-morphine SRTablet, extended release15 mgOralBard Pharmaceuticals (1990) IncNot applicableNot applicableCanada
Bar-morphine SRTablet, extended release200 mgOralBard Pharmaceuticals (1990) IncNot applicableNot applicableCanada
Bar-morphine SRTablet, extended release30 mgOralBard Pharmaceuticals (1990) IncNot applicableNot applicableCanada
Bar-morphine SRTablet, extended release60 mgOralBard Pharmaceuticals (1990) IncNot applicableNot applicableCanada
Doloral 1Syrup1 mgOralLaboratoire Atlas Inc1985-12-31Not applicableCanada
Doloral 5 Sirop 5mg/mlSyrup5 mgOralLaboratoire Atlas Inc1991-12-31Not applicableCanada
DuramorphInjection1 mg/mLEpidural; Intrathecal; IntravenousWest Ward Pharmaceutical Corp.1984-09-18Not applicableUs
DuramorphInjection.5 mg/mLEpidural; Intrathecal; IntravenousWest Ward Pharmaceutical Corp.1984-09-18Not applicableUs
Infumorph 200Injection, solution10 mg/mLEpidural; IntrathecalWest Ward Pharmaceutical Corp.1984-09-18Not applicableUs
Infumorph 500Injection, solution25 mg/mLEpidural; IntrathecalWest Ward Pharmaceutical Corp.1984-09-18Not applicableUs
KadianCapsule, extended release70 mg/1OralActavis Kadian LLC2012-05-07Not applicableUs
KadianCapsule, extended release60 mg/1OralLake Erie Medical DBA Quality Care Products LLC2012-02-29Not applicableUs
KadianCapsule, extended release40 mg/1OralActavis Pharma, Inc.2012-05-07Not applicableUs
KadianCapsule, extended release20 mg/1OralLake Erie Medical DBA Quality Care Products LLC2009-04-07Not applicableUs
KadianCapsule, extended release50 mgOralBgp Pharma Ulc1996-10-23Not applicableCanada
KadianCapsule, extended release80 mg/1OralSTAT Rx USA LLC2009-04-07Not applicableUs
KadianCapsule, extended release60 mg/1OralPhysicians Total Care, Inc.2008-01-16Not applicableUs
KadianCapsule, extended release20 mg/1Oralbryant ranch prepack2009-04-07Not applicableUs
KadianCapsule, extended release50 mg/1OralSTAT Rx USA LLC2009-04-07Not applicableUs
KadianCapsule, extended release20 mg/1OralActavis Pharma, Inc.2009-04-07Not applicableUs
KadianCapsule, extended release10 mg/1OralActavis Kadian LLC2009-04-07Not applicableUs
KadianCapsule, extended release100 mg/1OralPhysicians Total Care, Inc.2008-11-20Not applicableUs
KadianCapsule, extended release30 mg/1OralActavis Kadian LLC2009-04-07Not applicableUs
KadianCapsule, extended release20 mg/1OralLake Erie Medical DBA Quality Care Products LLC2011-12-21Not applicableUs
KadianCapsule, extended release50 mg/1OralActavis Pharma, Inc.2009-04-07Not applicableUs
KadianCapsule, extended release130 mg/1OralActavis Kadian LLC2012-05-07Not applicableUs
KadianCapsule, extended release100 mg/1OralLake Erie Medical DBA Quality Care Products LLC2012-02-29Not applicableUs
KadianCapsule, extended release100 mgOralBgp Pharma Ulc1996-10-25Not applicableCanada
KadianCapsule, extended release20 mg/1OralActavis Kadian LLC2009-04-07Not applicableUs
KadianCapsule, extended release10 mg/1OralPhysicians Total Care, Inc.2008-11-19Not applicableUs
KadianCapsule, extended release30 mg/1Oralbryant ranch prepack2009-04-07Not applicableUs
KadianCapsule, extended release30 mg/1OralSTAT Rx USA LLC2009-04-07Not applicableUs
KadianCapsule, extended release200 mg/1OralActavis Pharma, Inc.2009-04-07Not applicableUs
KadianCapsule, extended release80 mg/1OralActavis Kadian LLC2009-04-07Not applicableUs
KadianCapsule, extended release10 mg/1OralActavis Pharma, Inc.2009-04-07Not applicableUs
KadianCapsule, extended release60 mg/1OralActavis Kadian LLC2009-04-07Not applicableUs
KadianCapsule, extended release30 mg/1OralLake Erie Medical DBA Quality Care Products LLC2011-12-21Not applicableUs
KadianCapsule, extended release60 mg/1OralActavis Pharma, Inc.2009-04-07Not applicableUs
KadianCapsule, extended release150 mg/1OralActavis Kadian LLC2012-05-07Not applicableUs
KadianCapsule, extended release20 mg/1OralPhysicians Total Care, Inc.2001-11-07Not applicableUs
KadianCapsule, extended release80 mg/1OralLake Erie Medical DBA Quality Care Products LLC2012-02-29Not applicableUs
KadianCapsule, extended release30 mg/1OralLake Erie Medical DBA Quality Care Products LLC2009-04-07Not applicableUs
KadianCapsule, extended release10 mgOralBgp Pharma Ulc2001-12-11Not applicableCanada
KadianCapsule, extended release50 mg/1OralActavis Kadian LLC2009-04-07Not applicableUs
KadianCapsule, extended release200 mg/1OralSTAT Rx USA LLC2009-04-07Not applicableUs
KadianCapsule, extended release60 mg/1Oralbryant ranch prepack2009-04-07Not applicableUs
KadianCapsule, extended release20 mg/1OralSTAT Rx USA LLC2009-04-07Not applicableUs
KadianCapsule, extended release80 mg/1OralActavis Pharma, Inc.2009-04-07Not applicableUs
KadianCapsule, extended release30 mg/1OralPhysicians Total Care, Inc.2004-01-16Not applicableUs
KadianCapsule, extended release50 mg/1OralLake Erie Medical DBA Quality Care Products LLC2012-02-29Not applicableUs
KadianCapsule, extended release30 mg/1OralActavis Pharma, Inc.2009-04-07Not applicableUs
KadianCapsule, extended release40 mg/1OralActavis Kadian LLC2012-05-07Not applicableUs
KadianCapsule, extended release100 mg/1OralActavis Pharma, Inc.2009-04-07Not applicableUs
KadianCapsule, extended release200 mg/1OralActavis Kadian LLC2009-04-07Not applicableUs
KadianCapsule, extended release50 mg/1OralPhysicians Total Care, Inc.2001-11-07Not applicableUs
KadianCapsule, extended release60 mg/1OralSTAT Rx USA LLC2009-04-07Not applicableUs
KadianCapsule, extended release100 mg/1OralActavis Kadian LLC2009-04-07Not applicableUs
KadianCapsule, extended release10 mg/1OralLake Erie Medical DBA Quality Care Products LLC2012-02-29Not applicableUs
KadianCapsule, extended release100 mg/1OralSTAT Rx USA LLC2009-04-07Not applicableUs
KadianCapsule, extended release20 mgOralBgp Pharma Ulc1996-10-25Not applicableCanada
Kadian ERCapsule20 mg/1OralSt Marys Medical Park Pharmacy2010-12-21Not applicableUs
M-eslonCapsule, extended release15 mgOralEthypharm Inc1995-12-31Not applicableCanada
M-eslonCapsule, extended release100 mgOralEthypharm Inc1993-12-31Not applicableCanada
M-eslonCapsule, extended release60 mgOralEthypharm Inc1993-12-31Not applicableCanada
M-eslonCapsule, extended release10 mgOralEthypharm Inc1993-12-31Not applicableCanada
M-eslonCapsule, extended release200 mgOralEthypharm Inc1995-12-31Not applicableCanada
M-eslonCapsule, extended release30 mgOralEthypharm Inc1993-12-31Not applicableCanada
M-eslon IrCapsule10 mgOralEthypharm Inc2016-09-06Not applicableCanada
M-eslon IrCapsule20 mgOralEthypharm Inc2016-09-06Not applicableCanada
M-eslon IrCapsule30 mgOralEthypharm Inc2016-09-06Not applicableCanada
M-eslon IrCapsule5 mgOralEthypharm Inc2016-09-06Not applicableCanada
M.O.S. 10 Syrup 10mg/mlSyrup10 mgOralValeant Canada Lp Valeant Canada S.E.C.1985-12-312014-07-30Canada
M.O.S. 10 Tablets 10mgTablet10 mgOralValeant Canada Lp Valeant Canada S.E.C.1986-12-312014-07-30Canada
M.O.S. 20 Concentrate 20mg/mlSyrup20 mgOralValeant Canada Lp Valeant Canada S.E.C.1985-12-312014-07-30Canada
M.O.S. SR Tablets 30mgTablet, extended release30 mgOralValeant Canada Lp/valeant Canada s.e.c.1988-12-312016-07-08Canada
M.O.S. SR Tablets 60mgTablet, extended release60 mgOralValeant Canada Lp/valeant Canada s.e.c.1988-12-312016-07-08Canada
M.O.S. Sulphate 10mg TabTablet10 mgOralValeant Canada Lp/valeant Canada s.e.c.1993-12-312016-07-08Canada
M.O.S. Sulphate 25mg TabTablet25 mgOralValeant Canada Lp/valeant Canada s.e.c.1993-12-312016-07-08Canada
M.O.S. Sulphate 50mg TabTablet50 mgOralValeant Canada Lp/valeant Canada s.e.c.1993-12-312016-07-08Canada
M.O.S. Sulphate 5mg TabTablet5 mgOralValeant Canada Lp/valeant Canada s.e.c.1993-12-312016-07-08Canada
M.O.S. Syrup 1.0 mg/mlSyrup1 mgOralValeant Canada Lp Valeant Canada S.E.C.1980-12-312014-07-30Canada
M.O.S. Syrup 5mg/mlSyrup5 mgOralValeant Canada Lp Valeant Canada S.E.C.1981-12-312014-07-30Canada
M.O.S.- 10Suppository10 mgRectalValeant Canada Lp Valeant Canada S.E.C.1984-12-312014-07-30Canada
M.O.S.- 20Suppository20 mgRectalValeant Canada Lp Valeant Canada S.E.C.1984-12-312014-07-30Canada
M.O.S.- 30Suppository30 mgRectalValeant Canada Lp Valeant Canada S.E.C.1985-12-312014-07-30Canada
M.O.S.-20 Tab 20mgTablet20 mgOralValeant Canada Lp Valeant Canada S.E.C.1986-12-312014-07-30Canada
M.O.S.-40 Tab 40mgTablet40 mgOralValeant Canada Lp Valeant Canada S.E.C.1986-12-312014-07-30Canada
M.O.S.-50 Concentrate Liq 50mg/mlSyrup50 mgOralValeant Canada Lp Valeant Canada S.E.C.1986-12-312014-07-30Canada
M.O.S.-60 Tab 60mgTablet60 mgOralValeant Canada Lp Valeant Canada S.E.C.1986-12-312014-07-30Canada
MorphabondTablet, extended release100 mg/1OralInspirion Delivery Technologies, Llc2016-04-02Not applicableUs
MorphabondTablet, extended release60 mg/1OralInspirion Delivery Technologies, Llc2016-04-02Not applicableUs
MorphabondTablet, extended release30 mg/1OralInspirion Delivery Technologies, Llc2016-04-02Not applicableUs
MorphabondTablet, extended release15 mg/1OralInspirion Delivery Technologies, Llc2016-04-02Not applicableUs
Morphine Extra Forte Injection 50mg/ml USPSolution50 mgIntramuscular; Intravenous; SubcutaneousHospira Healthcare Corporation1990-12-31Not applicableCanada
Morphine Forte Injection 25mg/ml USPSolution25 mgIntramuscular; Intravenous; SubcutaneousHospira Healthcare Corporation1990-12-31Not applicableCanada
Morphine Hp 25 - 25mg/mlSolution25 mgIntramuscular; Intravenous; SubcutaneousSandoz Canada Incorporated1986-12-31Not applicableCanada
Morphine Hp 50 - 50mg/ml USPSolution50 mgIntramuscular; Intravenous; SubcutaneousSandoz Canada Incorporated1987-12-31Not applicableCanada
Morphine Lp EpiduralSolution1 mgEpidural; Intravenous; SubcutaneousSandoz Canada Incorporated1993-12-31Not applicableCanada
Morphine Lp EpiduralSolution0.5 mgEpidural; Intravenous; SubcutaneousSandoz Canada Incorporated1993-12-31Not applicableCanada
Morphine SRTablet, extended release30 mgOralSanis Health Inc2011-03-01Not applicableCanada
Morphine SRTablet, extended release100 mgOralSanis Health Inc2011-03-012014-08-01Canada
Morphine SRTablet, extended release60 mgOralSanis Health Inc2011-03-02Not applicableCanada
Morphine SRTablet, extended release200 mgOralSanis Health Inc2011-03-012014-08-01Canada
Morphine SRTablet, extended release15 mgOralSanis Health Inc2011-03-01Not applicableCanada
Morphine SulfateTablet30 mg/1OralH.J. Harkins Company, Inc.2008-03-17Not applicableUs
Morphine SulfateCapsule, extended release200 mg/1OralActavis Elizabeth LLC2011-11-11Not applicableUs
Morphine SulfateSolution10 mg/5mLOralAtlantic Biologicals Corps2008-03-17Not applicableUs
Morphine SulfateTablet30 mg/1OralSTAT Rx USA LLC2008-03-17Not applicableUs
Morphine SulfateCapsule, extended release50 mg/1OralPar Pharmaceutical Inc.2012-11-09Not applicableUs
Morphine SulfateCapsule, extended release10 mg/1OralActavis Elizabeth LLC2011-11-11Not applicableUs
Morphine SulfateInjection, solution5 mg/mLIntravenousHospira, Inc.1992-10-30Not applicableUs
Morphine SulfateInjection, solution5 mg/mLIntramuscular; IntravenousFresenius Kabi2013-02-14Not applicableUs
Morphine SulfateSolution10 mg/5mLOralPrecision Dose Inc.2016-02-29Not applicableUs
Morphine SulfateInjection, solution10 mg/mLIntravenousHospira, Inc.2011-11-14Not applicableUs
Morphine SulfateSolution20 mg/5mLOralWest Ward Pharmaceuticals Corp.2008-03-17Not applicableUs
Morphine SulfateSolution20 mg/5mLOralAtlantic Biologicals Corp.2016-09-06Not applicableUs
Morphine SulfateTablet15 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-03-19Not applicableUs
Morphine SulfateCapsule, extended release60 mg/1OralActavis Elizabeth LLC2011-11-11Not applicableUs
Morphine SulfateSolution100 mg/5mLOralPrecision Dose Inc.2013-08-16Not applicableUs
Morphine SulfateTablet15 mg/1OralPhysicians Total Care, Inc.2008-01-07Not applicableUs
Morphine SulfateInjection, solution2 mg/mLIntravenousHospira, Inc.2011-11-14Not applicableUs
Morphine SulfateTablet15 mg/1OralWest Ward Pharmaceuticals Corp2008-03-17Not applicableUs
Morphine SulfateInjection, solution8 mg/mLIntramuscular; IntravenousFresenius Kabi2013-02-14Not applicableUs
Morphine SulfateCapsule, extended release60 mg/1OralPar Pharmaceutical Inc.2012-11-09Not applicableUs
Morphine SulfateCapsule, extended release20 mg/1OralActavis Elizabeth LLC2011-11-11Not applicableUs
Morphine SulfateSolution, concentrate100 mg/5mLOralLannett Company, Inc.2011-06-23Not applicableUs
Morphine SulfateTablet30 mg/1OralPhysicians Total Care, Inc.2009-05-29Not applicableUs
Morphine SulfateInjection, solution15 mg/mLIntravenousHospira, Inc.2011-11-14Not applicableUs
Morphine SulfateSolution100 mg/5mLOralPrecision Dose Inc.2014-06-04Not applicableUs
Morphine SulfateSolution100 mg/5mLOralWest Ward Pharmaceuticals Corp.2008-03-17Not applicableUs
Morphine SulfateTablet30 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-12-13Not applicableUs
Morphine SulfateCapsule, extended release80 mg/1OralActavis Elizabeth LLC2011-11-11Not applicableUs
Morphine SulfateInjection, solution4 mg/mLIntravenousHospira, Inc.2011-11-14Not applicableUs
Morphine SulfateTablet30 mg/1OralWest Ward Pharmaceuticals Corp2008-03-17Not applicableUs
Morphine SulfateInjection, solution10 mg/mLIntramuscular; IntravenousFresenius Kabi2013-02-14Not applicableUs
Morphine SulfateCapsule, extended release80 mg/1OralPar Pharmaceutical Inc.2012-11-09Not applicableUs
Morphine SulfateCapsule, extended release30 mg/1OralActavis Elizabeth LLC2011-11-11Not applicableUs
Morphine SulfateInjection, solution.5 mg/mLIntravenousHospira, Inc.1992-10-30Not applicableUs
Morphine SulfateTablet30 mg/1Oralbryant ranch prepack2008-03-17Not applicableUs
Morphine SulfateInjection, solution2 mg/mLIntramuscular; IntravenousFresenius Kabi2013-02-14Not applicableUs
Morphine SulfateCapsule, extended release20 mg/1OralPar Pharmaceutical Inc.2012-11-09Not applicableUs
Morphine SulfateCapsule, extended release100 mg/1OralActavis Elizabeth LLC2011-11-11Not applicableUs
Morphine SulfateInjection10 mg/.7mLIntramuscularMeridian Medical Technologies, Inc.1990-07-12Not applicableUs
Morphine SulfateSolution100 mg/5mLOralWest Ward Pharmaceuticals Corp.2008-03-17Not applicableUs
Morphine SulfateTablet15 mg/1OralH.J. Harkins Company, Inc.2008-03-17Not applicableUs
Morphine SulfateInjection, solution8 mg/mLIntravenousHospira, Inc.2011-11-14Not applicableUs
Morphine SulfateSolution10 mg/5mLOralWest Ward Pharmaceuticals Corp.2008-03-17Not applicableUs
Morphine SulfateSolution20 mg/5mLOralAtlantic Biologicals Corps2008-03-17Not applicableUs
Morphine SulfateCapsule, extended release100 mg/1OralPar Pharmaceutical Inc.2012-11-09Not applicableUs
Morphine SulfateCapsule, extended release50 mg/1OralActavis Elizabeth LLC2011-11-11Not applicableUs
Morphine SulfateTablet30 mg/1OralDispensing Solutions, Inc.2008-03-17Not applicableUs
Morphine SulfateInjection, solution1 mg/mLIntravenousHospira, Inc.1992-10-30Not applicableUs
Morphine SulfateTablet15 mg/1OralSTAT Rx USA LLC2008-03-17Not applicableUs
Morphine SulfateTablet15 mg/1Oralbryant ranch prepack2008-03-17Not applicableUs
Morphine SulfateInjection, solution4 mg/mLIntramuscular; IntravenousFresenius Kabi2013-02-14Not applicableUs
Morphine SulfateCapsule, extended release30 mg/1OralPar Pharmaceutical Inc.2012-11-09Not applicableUs
Morphine SulfateSolution10 mg/5mLOralPhysicians Total Care, Inc.2005-09-12Not applicableUs
Morphine Sulfate Inj 10mg/ml USPLiquid10 mgIntramuscular; Intravenous; SubcutaneousSandoz Canada Incorporated1978-12-31Not applicableCanada
Morphine Sulfate Inj 15mg/ml USPLiquid15 mgIntramuscular; Intravenous; SubcutaneousSandoz Canada Incorporated1978-12-31Not applicableCanada
Morphine Sulfate Inj 1mg/ml USPSolution1 mgIntravenous; SubcutaneousSandoz Canada Incorporated1992-12-31Not applicableCanada
Morphine Sulfate Inj 2mg/ml USPSolution2 mgIntravenous; SubcutaneousSandoz Canada Incorporated1992-12-31Not applicableCanada
Morphine Sulfate Inj 5mg/ml USPSolution5 mgIntravenous; SubcutaneousSandoz Canada Incorporated1992-12-31Not applicableCanada
Morphine Sulfate Injection 10mg/ml USPSolution10 mgIntramuscular; Intravenous; SubcutaneousHospira Healthcare Corporation1988-12-31Not applicableCanada
Morphine Sulfate Injection 15mg/ml USPSolution15 mgIntramuscular; Intravenous; SubcutaneousHospira Healthcare Corporation1989-12-31Not applicableCanada
Morphine Sulfate Injection 1mg/mlSolution1 mgIntravenousHospira Healthcare Corporation1986-12-31Not applicableCanada
Morphine Sulfate Injection 2mg/ml USPSolution2 mgIntramuscular; Intravenous; SubcutaneousHospira Healthcare Corporation1989-12-31Not applicableCanada
Morphine Sulfate Injection 5mg/ml USPSolution5 mgIntravenousHospira Healthcare Corporation1986-12-31Not applicableCanada
Morphine Sulfate Injection SdzSolution2 mgIntramuscular; Intravenous; SubcutaneousSandoz Canada IncorporatedNot applicableNot applicableCanada
Morphine Sulfate Injection SdzSolution15 mgIntramuscular; Intravenous; SubcutaneousSandoz Canada IncorporatedNot applicableNot applicableCanada
Morphine Sulfate Injection SdzSolution10 mgIntramuscular; Intravenous; SubcutaneousSandoz Canada Incorporated2012-10-18Not applicableCanada
Morphine Sulfate Injection SdzSolution1 mgIntramuscular; Intravenous; SubcutaneousSandoz Canada IncorporatedNot applicableNot applicableCanada
Morphine Sulfate Injection USPLiquid2 mgIntramuscular; Intravenous; SubcutaneousSandoz Canada Incorporated2000-12-12Not applicableCanada
Morphine Sulphate Inj 1mg/ml BPLiquid1 mgIntravenous; SubcutaneousDavid Bull Laboratories (Canada) Inc.1993-12-311998-08-13Canada
Morphine Sulphate Injection 1mg/mlLiquid1 mgIntravenous; SubcutaneousHospira Healthcare Corporation1997-09-04Not applicableCanada
Morphine Sulphate Injection 2mg/mlLiquid2 mgIntravenous; SubcutaneousHospira Healthcare Corporation1997-09-04Not applicableCanada
Morphine Sulphate Injection 50mg/mlLiquid50 mgIntramuscular; Intravenous; SubcutaneousHospira Healthcare Corporation1997-09-11Not applicableCanada
Morphine Sulphate Injection B.P. 25mg/mlLiquid25 mgIntramuscular; Intravenous; SubcutaneousDavid Bull Laboratories (Canada) Inc.1994-12-311997-08-14Canada
Morphine Sulphate Injection B.P. 50mg/mlLiquid50 mgIntramuscular; Intravenous; SubcutaneousDavid Bull Laboratories (Canada) Inc.1994-12-311998-08-13Canada
Morphine Sulphate Injection Bp 2mg/mlLiquid2 mgIntravenous; SubcutaneousDavid Bull Laboratories (Canada) Inc.1993-12-311998-08-13Canada
Morphine Sulphate Injection, USPLiquid25 mgIntravenousInternational Medication Systems Ltd.1993-12-311997-08-15Canada
Morphine Sulphate Injection, USP Liq50mg/mlLiquid50 mgIntravenousInternational Medication Systems Ltd.1993-12-311997-08-15Canada
Morphine Sulphate Injection,usp Liq 1.1mg/mlLiquid1.1 mgIntravenousInternational Medication Systems Ltd.1993-12-311997-08-15Canada
Morphine-epd Injection 0.5mg/ml USPSolution0.5 mgEpiduralHospira Healthcare Corporation1992-12-31Not applicableCanada
Morphine-epd Injection 1mg/ml USPSolution1 mgEpiduralHospira Healthcare Corporation1992-12-31Not applicableCanada
Ms ContinTablet, film coated, extended release100 mg/1OralPurdue Pharma LP1987-07-01Not applicableUs
Ms ContinTablet, film coated, extended release100 mg/1OralCardinal Health1987-07-01Not applicableUs
Ms ContinTablet, film coated, extended release15 mg/1OralPurdue Pharma LP1987-07-01Not applicableUs
Ms ContinTablet, film coated, extended release200 mg/1OralPurdue Pharma LP1987-07-01Not applicableUs
Ms ContinTablet, film coated, extended release15 mg/1OralLake Erie Medical DBA Quality Care Products LLC2011-01-31Not applicableUs
Ms ContinTablet, film coated, extended release30 mg/1OralPurdue Pharma LP1987-07-01Not applicableUs
Ms ContinTablet, film coated, extended release30 mg/1OralCardinal Health1987-07-01Not applicableUs
Ms ContinTablet, film coated, extended release60 mg/1OralPurdue Pharma LP1987-07-01Not applicableUs
Ms ContinTablet, film coated, extended release60 mg/1OralCardinal Health1987-07-01Not applicableUs
Ms Contin CRTablet, film coated, extended release60 mg/1OralSTAT Rx USA LLC1987-07-01Not applicableUs
Ms Contin Srt 100mgTablet, extended release100 mgOralPurdue Pharma1993-12-31Not applicableCanada
Ms Contin Srt 15mgTablet, extended release15 mgOralPurdue Pharma1993-12-31Not applicableCanada
Ms Contin Srt 200mgTablet, extended release200 mgOralPurdue Pharma1993-12-31Not applicableCanada
Ms Contin Srt 30mgTablet, extended release30 mgOralPurdue Pharma1993-12-31Not applicableCanada
Ms Contin Srt 60mgTablet, extended release60 mgOralPurdue Pharma1993-12-31Not applicableCanada
Ms Contin Suppositories - 30mgSuppository, extended release30 mgRectalPurdue Pharma1995-12-312003-07-29Canada
Ms Contin Suppositories - 100mgSuppository, extended release100 mgRectalPurdue Pharma1995-12-312003-07-29Canada
Ms Contin Suppositories - 200mgSuppository, extended release200 mgRectalPurdue Pharma1995-12-312003-07-29Canada
Ms Contin Suppositories - 60mgSuppository, extended release60 mgRectalPurdue Pharma1995-12-312003-07-29Canada
Ms Contin TabletsTablet, extended release5 mgOralPurdue PharmaNot applicableNot applicableCanada
Ms Contin XL CapsulesCapsule, extended release30 mgOralPurdue PharmaNot applicableNot applicableCanada
Ms Contin XL CapsulesCapsule, extended release150 mgOralPurdue PharmaNot applicableNot applicableCanada
Ms Contin XL CapsulesCapsule, extended release60 mgOralPurdue PharmaNot applicableNot applicableCanada
Ms Contin XL CapsulesCapsule, extended release200 mgOralPurdue PharmaNot applicableNot applicableCanada
Ms Contin XL CapsulesCapsule, extended release90 mgOralPurdue PharmaNot applicableNot applicableCanada
Ms Contin XL CapsulesCapsule, extended release120 mgOralPurdue PharmaNot applicableNot applicableCanada
Ms Ir Sup 30mgSuppository30 mgRectalPurdue Pharma1991-12-312003-07-29Canada
Ms Ir Sup 10mgSuppository10 mgRectalPurdue Pharma1991-12-312003-07-29Canada
Ms Ir Sup 20mgSuppository20 mgRectalPurdue Pharma1991-12-312003-07-29Canada
Ms Ir Tab 10mgTablet10 mgOralPurdue Pharma1993-12-31Not applicableCanada
Ms Ir Tab 20mgTablet20 mgOralPurdue Pharma1991-12-31Not applicableCanada
Ms Ir Tab 30mgTablet30 mgOralPurdue Pharma1991-12-31Not applicableCanada
Ms Ir Tab 5mgTablet5 mgOralPurdue Pharma1991-12-31Not applicableCanada
Ntp-morphine SRTablet, extended release30 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-morphine SRTablet, extended release60 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-morphine SRTablet, extended release100 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-morphine SRTablet, extended release15 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-morphine SRTablet, extended release200 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Opium TinctureTincture10 mgOralD.C. Labs Limited1951-12-312003-07-11Canada
Oramorph SR Tablets 100mgTablet, extended release100 mgOralRoxane Labs, Division Of Boehringer Ingelheim1992-12-312001-07-30Canada
Oramorph SR Tablets 30mgTablet, extended release30 mgOralRoxane Labs, Division Of Boehringer Ingelheim1992-12-312002-07-25Canada
Oramorph SR Tablets 60mgTablet, extended release60 mgOralRoxane Labs, Division Of Boehringer Ingelheim1992-12-312002-07-25Canada
PMS-morphine Sulfate SR 100 mgTablet, extended release100 mgOralPharmascience Inc2007-12-172012-11-09Canada
PMS-morphine Sulfate SR 15 mgTablet, extended release15 mgOralPharmascience Inc2002-02-202012-11-09Canada
PMS-morphine Sulfate SR 200 mgTablet, extended release200 mgOralPharmascience Inc2007-12-172012-11-09Canada
PMS-morphine Sulfate SR 30 mgTablet, extended release30 mgOralPharmascience Inc2002-02-202012-11-09Canada
PMS-morphine Sulfate SR 60 mgTablet, extended release60 mgOralPharmascience Inc2002-02-202012-11-09Canada
Ratio-morphineSyrup5 mgOralTeva Canada Limited1985-12-31Not applicableCanada
Ratio-morphineSyrup20 mgOralTeva Canada Limited1986-12-31Not applicableCanada
Ratio-morphineSyrup10 mgOralTeva Canada Limited1986-12-31Not applicableCanada
Ratio-morphineSyrup1 mgOralTeva Canada Limited1984-12-31Not applicableCanada
Sandoz Morphine SRTablet, extended release15 mgOralSandoz Canada Incorporated2001-11-14Not applicableCanada
Sandoz Morphine SRTablet, extended release30 mgOralSandoz Canada Incorporated2001-11-14Not applicableCanada
Sandoz Morphine SRTablet, extended release60 mgOralSandoz Canada Incorporated2001-11-14Not applicableCanada
Statex Dps 50mg/mlSolution / drops50 mgOralPaladin Labs Inc1986-12-31Not applicableCanada
Statex Drops 20mg/mlSolution / drops20 mgOralPaladin Labs Inc1984-12-31Not applicableCanada
Statex Suppositories 20mgSuppository20 mgRectalPaladin Labs Inc1985-12-31Not applicableCanada
Statex Suppositories 30mgSuppository30 mgRectalPaladin Labs Inc1997-08-04Not applicableCanada
Statex Suppositories 5mgSuppository5 mgRectalPaladin Labs Inc1997-08-04Not applicableCanada
Statex Syrup 10mg/mlSyrup10 mgOralPaladin Labs Inc1987-12-31Not applicableCanada
Statex Syrup 1mg/mlSyrup1 mgOralPaladin Labs Inc1984-12-31Not applicableCanada
Statex Syrup 5mg/mlSyrup5 mgOralPaladin Labs Inc1984-12-31Not applicableCanada
Statex Tab 10mgTablet10 mgOralPaladin Labs Inc1985-12-31Not applicableCanada
Statex Tab 5mgTablet5 mgOralPaladin Labs Inc1985-12-31Not applicableCanada
Statex Tablet 25mgTablet25 mgOralPaladin Labs Inc1985-12-31Not applicableCanada
Statex Tablets 50mgTablet50 mgOralPaladin Labs Inc1986-12-31Not applicableCanada
Statex-suppositories 10mgSuppository10 mgRectalPaladin Labs Inc1985-12-31Not applicableCanada
Teva-morphine SRTablet, extended release100 mgOralTeva Canada Limited2008-04-01Not applicableCanada
Teva-morphine SRTablet, extended release15 mgOralTeva Canada Limited2009-03-25Not applicableCanada
Teva-morphine SRTablet, extended release200 mgOralTeva Canada Limited2008-04-01Not applicableCanada
Teva-morphine SRTablet, extended release30 mgOralTeva Canada Limited2009-03-25Not applicableCanada
Teva-morphine SRTablet, extended release60 mgOralTeva Canada Limited2008-04-01Not applicableCanada
ZomorphCapsule, extended release60 mgOralEthypharm IncNot applicableNot applicableCanada
ZomorphCapsule, extended release120 mgOralEthypharm IncNot applicableNot applicableCanada
ZomorphCapsule, extended release200 mgOralEthypharm IncNot applicableNot applicableCanada
ZomorphCapsule, extended release20 mgOralEthypharm IncNot applicableNot applicableCanada
ZomorphCapsule, extended release40 mgOralEthypharm IncNot applicableNot applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Morphine SulfateTablet, film coated, extended release15 mg/1OralH.J. Harkins Company, Inc.2011-01-14Not applicableUs
Morphine SulfateSolution20 mg/mLOralTris Pharma Inc2015-09-21Not applicableUs
Morphine SulfateTablet, film coated, extended release100 mg/1OralWatson Laboratories, Inc.1987-05-01Not applicableUs
Morphine SulfateTablet, extended release200 mg/1OralQualitest Pharmaceuticals1998-10-31Not applicableUs
Morphine SulfateTablet, film coated, extended release15 mg/1OralRanbaxy Pharmaceuticals Inc.2012-05-11Not applicableUs
Morphine SulfateCapsule, extended release20 mg/1OralLake Erie Medical DBA Quality Care Products LLC2013-06-30Not applicableUs
Morphine SulfateTablet, film coated, extended release100 mg/1OralMayne Pharma Inc.2016-11-01Not applicableUs
Morphine SulfateCapsule, extended release120 mg/1OralActavis Pharma, Inc.2014-02-04Not applicableUs
Morphine SulfateTablet, film coated, extended release60 mg/1OralMylan Pharmaceuticals Inc.2011-10-26Not applicableUs
Morphine SulfateCapsule, extended release50 mg/1OralPar Pharmaceutical Inc.2011-11-10Not applicableUs
Morphine SulfateCapsule, extended release20 mg/1OralUpsher Smith Laboratories, Inc.2013-06-30Not applicableUs
Morphine SulfateCapsule, extended release50 mg/1OralWatson Laboratories, Inc.2011-11-10Not applicableUs
Morphine SulfateTablet, extended release100 mg/1OralMallinckrodt, Inc.2010-10-21Not applicableUs
Morphine SulfateTablet, film coated, extended release15 mg/1OralEthex Corporation2009-12-03Not applicableUs
Morphine SulfateTablet, film coated, extended release15 mg/1Oralbryant ranch prepack2011-01-14Not applicableUs
Morphine SulfateTablet, film coated, extended release30 mg/1OralSt Marys Medical Park Pharmacy2016-04-01Not applicableUs
Morphine SulfateTablet, extended release60 mg/1OralNovel Laboratories, Inc.2015-12-16Not applicableUs
Morphine SulfateTablet, extended release15 mg/1OralZydus Pharmaceuticals (USA) Inc.2015-07-09Not applicableUs
Morphine SulfateTablet, film coated, extended release15 mg/1OralActavis Pharma, Inc.2015-10-26Not applicableUs
Morphine SulfateInjection, solution1 mg/mLEpidural; Intrathecal; IntravenousHospira, Inc.1988-05-112016-10-13Us
Morphine SulfateTablet, film coated, extended release100 mg/1OralPd Rx Pharmaceuticals, Inc.1987-05-01Not applicableUs
Morphine SulfateTablet, extended release15 mg/1OralPhysicians Total Care, Inc.2004-08-10Not applicableUs
Morphine SulfateInjection4 mg/mLIntravenousWest Ward Pharmaceuticals Corp.2015-06-03Not applicableUs
Morphine SulfateCapsule, extended release60 mg/1OralImpax Generics2016-04-12Not applicableUs
Morphine SulfateTablet, film coated, extended release60 mg/1OralRanbaxy Pharmaceuticals Inc.2012-05-11Not applicableUs
Morphine SulfateTablet, extended release60 mg/1OralAmerican Health Packaging2011-08-01Not applicableUs
Morphine SulfateTablet, extended release15 mg/1OralMallinckrodt, Inc.2010-10-21Not applicableUs
Morphine SulfateTablet, film coated, extended release15 mg/1OralMayne Pharma Inc.2016-11-01Not applicableUs
Morphine SulfateCapsule, extended release30 mg/1OralActavis Pharma, Inc.2014-02-04Not applicableUs
Morphine SulfateTablet, extended release200 mg/1OralZydus Pharmaceuticals (USA) Inc.2015-07-09Not applicableUs
Morphine SulfateTablet, film coated, extended release200 mg/1OralActavis Pharma, Inc.2015-10-26Not applicableUs
Morphine SulfateCapsule, extended release80 mg/1OralUpsher Smith Laboratories, Inc.2013-06-30Not applicableUs
Morphine SulfateTablet, film coated, extended release15 mg/1OralWatson Laboratories, Inc.1987-05-01Not applicableUs
Morphine SulfateTablet, extended release30 mg/1OralQualitest Pharmaceuticals1998-10-31Not applicableUs
Morphine SulfateTablet, film coated, extended release200 mg/1OralEthex Corporation2009-01-01Not applicableUs
Morphine SulfateTablet, film coated, extended release60 mg/1OralLupin Pharmaceuticals,inc.2015-12-16Not applicableUs
Morphine SulfateTablet, film coated, extended release15 mg/1OralPd Rx Pharmaceuticals, Inc.1987-05-01Not applicableUs
Morphine SulfateTablet, film coated, extended release30 mg/1OralH.J. Harkins Company, Inc.2011-01-14Not applicableUs
Morphine SulfateSolution10 mg/5mLOralTris Pharma Inc2015-05-31Not applicableUs
Morphine SulfateTablet, film coated, extended release200 mg/1OralWatson Laboratories, Inc.1987-05-01Not applicableUs
Morphine SulfateCapsule, extended release20 mg/1OralImpax Generics2016-04-12Not applicableUs
Morphine SulfateTablet, film coated, extended release30 mg/1OralRanbaxy Pharmaceuticals Inc.2012-05-11Not applicableUs
Morphine SulfateCapsule, extended release30 mg/1OralLake Erie Medical DBA Quality Care Products LLC2013-06-30Not applicableUs
Morphine SulfateTablet, film coated, extended release15 mg/1OralLake Erie Medical DBA Quality Care Products LLC2015-10-26Not applicableUs
Morphine SulfateCapsule, extended release45 mg/1OralActavis Pharma, Inc.2014-02-04Not applicableUs
Morphine SulfateTablet, film coated, extended release100 mg/1OralMylan Pharmaceuticals Inc.2011-10-26Not applicableUs
Morphine SulfateCapsule, extended release60 mg/1OralPar Pharmaceutical Inc.2011-11-10Not applicableUs
Morphine SulfateCapsule, extended release30 mg/1OralUpsher Smith Laboratories, Inc.2013-06-30Not applicableUs
Morphine SulfateCapsule, extended release60 mg/1OralWatson Laboratories, Inc.2011-11-10Not applicableUs
Morphine SulfateInjection, solution.5 mg/mLEpidural; Intrathecal; IntravenousHospira, Inc.1992-09-30Not applicableUs
Morphine SulfateTablet, film coated, extended release30 mg/1OralEthex Corporation2010-04-22Not applicableUs
Morphine SulfateTablet, film coated, extended release30 mg/1Oralbryant ranch prepack2011-01-14Not applicableUs
Morphine SulfateTablet, extended release100 mg/1OralNovel Laboratories, Inc.2015-12-16Not applicableUs
Morphine SulfateTablet, extended release30 mg/1OralZydus Pharmaceuticals (USA) Inc.2015-07-09Not applicableUs
Morphine SulfateTablet, film coated, extended release30 mg/1OralActavis Pharma, Inc.2015-10-26Not applicableUs
Morphine SulfateTablet, extended release100 mg/1OralAmerican Health Packaging2011-08-01Not applicableUs
Morphine SulfateTablet, extended release200 mg/1OralMallinckrodt, Inc.2010-10-21Not applicableUs
Morphine SulfateSolution100 mg/5mLOralPaddock Laboratories, LLC2012-08-17Not applicableUs
Morphine SulfateSolution20 mg/mLOralSafecor Health, LLC2013-01-17Not applicableUs
Morphine SulfateTablet, extended release100 mg/1OralPhysicians Total Care, Inc.2006-05-17Not applicableUs
Morphine SulfateInjection8 mg/mLIntravenousWest Ward Pharmaceuticals Corp.2015-06-03Not applicableUs
Morphine SulfateCapsule, extended release80 mg/1OralImpax Generics2016-04-12Not applicableUs
Morphine SulfateTablet, extended release60 mg/1OralQualitest Pharmaceuticals1998-10-31Not applicableUs
Morphine SulfateTablet, film coated, extended release30 mg/1OralDIRECT RX2015-01-01Not applicableUs
Morphine SulfateTablet, film coated, extended release100 mg/1OralLupin Pharmaceuticals,inc.2015-12-16Not applicableUs
Morphine SulfateSolution10 mg/5mLOralVista Pharm Inc.2012-03-01Not applicableUs
Morphine SulfateTablet, film coated, extended release30 mg/1OralMayne Pharma Inc.2016-11-01Not applicableUs
Morphine SulfateCapsule, extended release60 mg/1OralActavis Pharma, Inc.2014-02-04Not applicableUs
Morphine SulfateTablet, film coated, extended release15 mg/1OralMylan Pharmaceuticals Inc.2011-10-26Not applicableUs
Morphine SulfateCapsule, extended release100 mg/1OralUpsher Smith Laboratories, Inc.2013-06-30Not applicableUs
Morphine SulfateTablet, film coated, extended release30 mg/1OralWatson Laboratories, Inc.1987-05-01Not applicableUs
Morphine SulfateTablet, film coated, extended release30 mg/1OralPd Rx Pharmaceuticals, Inc.1987-05-01Not applicableUs
Morphine SulfateTablet, extended release30 mg/1OralPhysicians Total Care, Inc.2005-06-30Not applicableUs
Morphine SulfateSolution20 mg/5mLOralQualitest Pharmaceuticals2015-10-302016-10-18Us
Morphine SulfateCapsule, extended release30 mg/1OralImpax Generics2016-04-12Not applicableUs
Morphine SulfateTablet, film coated, extended release100 mg/1OralRanbaxy Pharmaceuticals Inc.2012-05-11Not applicableUs
Morphine SulfateTablet, extended release15 mg/1OralAmerican Health Packaging2011-08-01Not applicableUs
Morphine SulfateTablet, film coated, extended release60 mg/1OralLake Erie Medical DBA Quality Care Products LLC2015-10-26Not applicableUs
Morphine SulfateCapsule, extended release75 mg/1OralActavis Pharma, Inc.2014-02-04Not applicableUs
Morphine SulfateTablet, film coated, extended release200 mg/1OralMylan Pharmaceuticals Inc.2011-10-26Not applicableUs
Morphine SulfateCapsule, extended release80 mg/1OralPar Pharmaceutical Inc.2011-11-10Not applicableUs
Morphine SulfateCapsule, extended release50 mg/1OralUpsher Smith Laboratories, Inc.2013-06-30Not applicableUs
Morphine SulfateCapsule, extended release100 mg/1OralWatson Laboratories, Inc.2011-11-10Not applicableUs
Morphine SulfateInjection, solution1 mg/mLEpidural; Intrathecal; IntravenousHospira, Inc.1992-09-30Not applicableUs
Morphine SulfateTablet, film coated, extended release60 mg/1OralEthex Corporation2010-04-22Not applicableUs
Morphine SulfateTablet, film coated, extended release15 mg/1OralLupin Pharmaceuticals,inc.2015-12-16Not applicableUs
Morphine SulfateSolution20 mg/5mLOralNostrum Laboratories, Inc.2014-02-05Not applicableUs
Morphine SulfateTablet, extended release200 mg/1OralNovel Laboratories, Inc.2015-12-16Not applicableUs
Morphine SulfateTablet, extended release60 mg/1OralZydus Pharmaceuticals (USA) Inc.2015-07-09Not applicableUs
Morphine SulfateTablet, film coated, extended release60 mg/1OralActavis Pharma, Inc.2015-10-26Not applicableUs
Morphine SulfateInjection10 mg/mLIntravenousWest Ward Pharmaceuticals Corp.2015-06-03Not applicableUs
Morphine SulfateCapsule, extended release100 mg/1OralImpax Generics2016-04-12Not applicableUs
Morphine SulfateTablet, film coated, extended release15 mg/1Oralbryant ranch prepack2010-03-26Not applicableUs
Morphine SulfateTablet, extended release15 mg/1OralNovel Laboratories, Inc.2015-12-16Not applicableUs
Morphine SulfateTablet, extended release30 mg/1OralMallinckrodt, Inc.2010-10-21Not applicableUs
Morphine SulfateCapsule, extended release20 mg/1OralWatson Laboratories, Inc.2011-11-10Not applicableUs
Morphine SulfateCapsule, extended release20 mg/1OralPar Pharmaceutical Inc.2011-11-10Not applicableUs
Morphine SulfateTablet, film coated, extended release15 mg/1OralSTAT Rx USA LLC2011-01-14Not applicableUs
Morphine SulfateTablet, film coated, extended release60 mg/1OralWatson Laboratories, Inc.1987-05-01Not applicableUs
Morphine SulfateTablet, extended release100 mg/1OralQualitest Pharmaceuticals1998-10-31Not applicableUs
Morphine SulfateTablet, film coated, extended release15 mg/1OralDIRECT RX2015-01-01Not applicableUs
Morphine SulfateTablet, film coated, extended release200 mg/1OralLupin Pharmaceuticals,inc.2015-12-16Not applicableUs
Morphine SulfateSolution20 mg/5mLOralVista Pharm Inc.2012-03-01Not applicableUs
Morphine SulfateTablet, film coated, extended release60 mg/1OralMayne Pharma Inc.2016-11-01Not applicableUs
Morphine SulfateCapsule, extended release90 mg/1OralActavis Pharma, Inc.2014-02-04Not applicableUs
Morphine SulfateTablet, film coated, extended release30 mg/1OralMylan Pharmaceuticals Inc.2011-10-26Not applicableUs
Morphine SulfateTablet, film coated, extended release60 mg/1OralPd Rx Pharmaceuticals, Inc.1987-05-01Not applicableUs
Morphine SulfateTablet, extended release60 mg/1OralPhysicians Total Care, Inc.2004-04-26Not applicableUs
Morphine SulfateSolution10 mg/5mLOralQualitest Pharmaceuticals2015-11-252016-10-18Us
Morphine SulfateCapsule, extended release50 mg/1OralImpax Generics2016-04-12Not applicableUs
Morphine SulfateTablet, film coated, extended release200 mg/1OralRanbaxy Pharmaceuticals Inc.2012-05-11Not applicableUs
Morphine SulfateTablet, extended release30 mg/1OralAmerican Health Packaging2011-08-01Not applicableUs
Morphine SulfateSolution20 mg/mLOralMallinckrodt, Inc.2011-10-03Not applicableUs
Morphine SulfateInjection, solution.5 mg/mLEpidural; Intrathecal; IntravenousHospira, Inc.1988-05-112016-10-13Us
Morphine SulfateCapsule, extended release100 mg/1OralPar Pharmaceutical Inc.2011-11-10Not applicableUs
Morphine SulfateCapsule, extended release60 mg/1OralUpsher Smith Laboratories, Inc.2013-06-30Not applicableUs
Morphine SulfateCapsule, extended release80 mg/1OralWatson Laboratories, Inc.2011-11-10Not applicableUs
Morphine SulfateTablet, extended release15 mg/1OralQualitest Pharmaceuticals1998-10-31Not applicableUs
Morphine SulfateTablet, film coated, extended release100 mg/1OralEthex Corporation2009-01-01Not applicableUs
Morphine SulfateTablet, film coated, extended release30 mg/1OralLupin Pharmaceuticals,inc.2015-12-16Not applicableUs
Morphine SulfateTablet, film coated, extended release30 mg/1OralLake Erie Medical DBA Quality Care Products LLC2015-10-26Not applicableUs
Morphine SulfateTablet, extended release100 mg/1OralZydus Pharmaceuticals (USA) Inc.2015-07-09Not applicableUs
Morphine SulfateTablet, film coated, extended release100 mg/1OralActavis Pharma, Inc.2015-10-26Not applicableUs
Morphine SulfateCapsule, extended release10 mg/1OralUpsher Smith Laboratories, Inc.2013-06-30Not applicableUs
Morphine SulfateTablet, film coated, extended release15 mg/1OralSt Marys Medical Park Pharmacy2016-04-01Not applicableUs
Morphine SulfateTablet, extended release30 mg/1OralNovel Laboratories, Inc.2015-12-16Not applicableUs
Morphine SulfateSolution100 mg/5mLOralPharmaceutical Associates, Inc.2016-11-14Not applicableUs
Morphine SulfateTablet, extended release60 mg/1OralMallinckrodt, Inc.2010-10-21Not applicableUs
Morphine SulfateCapsule, extended release30 mg/1OralWatson Laboratories, Inc.2011-11-10Not applicableUs
Morphine SulfateCapsule, extended release30 mg/1OralPar Pharmaceutical Inc.2011-11-10Not applicableUs
Morphine SulfateSolution20 mg/5mLOralCaraco Pharmaceutical Laboratories, Ltd.2012-01-312016-11-15Us
Morphine Sulfate ERTablet30 mg/1OralLake Erie Medical DBA Quality Care Products LLC2010-04-07Not applicableUs
Morphine Sulfate Extended ReleaseTablet, film coated, extended release200 mg/1OralRhodes Pharmaceuticals L. P.2011-01-14Not applicableUs
Morphine Sulfate Extended ReleaseTablet, film coated, extended release15 mg/1OralAmerican Health Packaging2013-06-212016-08-31Us
Morphine Sulfate Extended ReleaseTablet, film coated, extended release100 mg/1OralLake Erie Medical DBA Quality Care Products LLC2011-01-14Not applicableUs
Morphine Sulfate Extended ReleaseTablet, film coated, extended release30 mg/1OralPd Rx Pharmaceuticals, Inc.2011-01-14Not applicableUs
Morphine Sulfate Extended ReleaseTablet, film coated, extended release60 mg/1OralLake Erie Medical DBA Quality Care Products LLC2011-01-14Not applicableUs
Morphine Sulfate Extended ReleaseTablet, film coated, extended release30 mg/1OralMajor Pharmaceuticals2011-01-14Not applicableUs
Morphine Sulfate Extended ReleaseTablet, film coated, extended release30 mg/1OralRhodes Pharmaceuticals L. P.2011-01-14Not applicableUs
Morphine Sulfate Extended ReleaseTablet, extended release15 mg/1OralLake Erie Medical DBA Quality Care Products LLC2010-09-17Not applicableUs
Morphine Sulfate Extended ReleaseTablet, film coated, extended release200 mg/1Oralbryant ranch prepack2011-01-14Not applicableUs
Morphine Sulfate Extended ReleaseTablet, film coated, extended release30 mg/1OralAmerican Health Packaging2013-06-212016-09-30Us
Morphine Sulfate Extended ReleaseTablet, film coated, extended release15 mg/1OralPd Rx Pharmaceuticals, Inc.2011-01-14Not applicableUs
Morphine Sulfate Extended ReleaseTablet, film coated, extended release60 mg/1OralMajor Pharmaceuticals2011-01-14Not applicableUs
Morphine Sulfate Extended ReleaseTablet, film coated, extended release15 mg/1OralLake Erie Medical DBA Quality Care Products LLC2011-01-14Not applicableUs
Morphine Sulfate Extended ReleaseTablet, film coated, extended release60 mg/1OralRhodes Pharmaceuticals L. P.2011-01-14Not applicableUs
Morphine Sulfate Extended ReleaseTablet, film coated, extended release100 mg/1Oralbryant ranch prepack2011-01-14Not applicableUs
Morphine Sulfate Extended ReleaseTablet, film coated, extended release200 mg/1OralLake Erie Medical DBA Quality Care Products LLC2011-01-14Not applicableUs
Morphine Sulfate Extended ReleaseTablet, film coated, extended release100 mg/1OralMajor Pharmaceuticals2011-01-14Not applicableUs
Morphine Sulfate Extended ReleaseTablet, film coated, extended release100 mg/1OralRhodes Pharmaceuticals L. P.2011-01-14Not applicableUs
Morphine Sulfate Extended ReleaseTablet60 mg/1OralLake Erie Medical DBA Quality Care Products LLC2010-08-19Not applicableUs
Morphine Sulfate Extended ReleaseTablet, film coated, extended release15 mg/1OralMajor Pharmaceuticals2011-01-14Not applicableUs
Morphine Sulfate Extended ReleaseTablet, film coated, extended release15 mg/1OralRhodes Pharmaceuticals L. P.2011-01-14Not applicableUs
Morphine Sulfate Extended ReleaseTablet, film coated, extended release60 mg/1Oralbryant ranch prepack2011-01-14Not applicableUs
Morphine Sulfate Extended ReleaseTablet, film coated, extended release30 mg/1OralLake Erie Medical DBA Quality Care Products LLC2011-01-14Not applicableUs
Morphine Sulfate Extended ReleaseTablet, film coated, extended release60 mg/1OralPd Rx Pharmaceuticals, Inc.2011-01-14Not applicableUs
Morphine Sulfate Extended ReleaseTablet30 mg/1Oralbryant ranch prepack2010-03-18Not applicableUs
Morphine Sulfate Extended-releaseTablet100 mg/1OralSun Pharmaceutical Industries, Inc.2016-09-13Not applicableUs
Morphine Sulfate Extended-releaseTablet, extended release30 mg/1OralSTAT Rx USA LLC2010-10-21Not applicableUs
Morphine Sulfate Extended-releaseTablet15 mg/1OralSun Pharmaceutical Industries, Inc.2016-09-13Not applicableUs
Morphine Sulfate Extended-releaseTablet60 mg/1Oralbryant ranch prepack2010-10-21Not applicableUs
Morphine Sulfate Extended-releaseTablet100 mg/1OralLake Erie Medical Surgical & Supply DBA Quality Care Products LLC2011-07-28Not applicableUs
Morphine Sulfate Extended-releaseTablet30 mg/1OralSun Pharmaceutical Industries, Inc.2016-09-13Not applicableUs
Morphine Sulfate Extended-releaseTablet, extended release15 mg/1OralSTAT Rx USA LLC2010-10-21Not applicableUs
Morphine Sulfate Extended-releaseTablet200 mg/1OralSun Pharmaceutical Industries, Inc.2016-09-13Not applicableUs
Morphine Sulfate Extended-releaseTablet200 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-03-20Not applicableUs
Morphine Sulfate Extended-releaseTablet60 mg/1OralSun Pharmaceutical Industries, Inc.2016-09-13Not applicableUs
Morphine Sulfate Oral SolutionSolution10 mg/5mLOralNostrum Laboratories, Inc.2014-02-05Not applicableUs
Morphine Sulfate Oral SolutionSolution10 mg/5mLOralCaraco Pharmaceutical Laboratories, Ltd.2012-01-312016-11-15Us
Morphine Sulfate Oral Solution CiiSolution100 mg/5mLOralNostrum Laboratories, Inc.2016-10-06Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Morphine SulfateSuppository5 mg/1RectalPaddock Laboratories, LLC1990-09-01Not applicableUs
Morphine SulfateInjection, solution.5 mg/mLIntrathecal; IntravenousCantrell Drug Company2012-01-23Not applicableUs
Morphine SulfateInjection1 mg/mLIntravenousInternational Medication Systems, Limited1987-03-27Not applicableUs
Morphine SulfateInjection5 mg/mLIntramuscular; Intravenous; SubcutaneousWest Ward Pharmaceutical Corp.1971-01-01Not applicableUs
Morphine SulfateInjection5 mg/mLIntramuscular; Intravenous; SubcutaneousBaxter Healthcare Corporation2010-05-262015-12-29Us
Morphine SulfateInjection10 mg/mLIntramuscular; Intravenous; SubcutaneousWest Ward Pharmaceutical Corp.1971-01-01Not applicableUs
Morphine SulfateInjection, solution25 mg/mLIntravenousHospira, Inc.1991-04-11Not applicableUs
Morphine SulfateSuppository10 mg/1RectalPaddock Laboratories, LLC1990-09-01Not applicableUs
Morphine SulfateInjection, solution1 mg/mLIntravenousCantrell Drug Company2013-09-09Not applicableUs
Morphine SulfateInjection, solution, concentrate50 mg/mLIntravenousHospira, Inc.1996-03-14Not applicableUs
Morphine SulfateInjection8 mg/mLIntramuscular; Intravenous; SubcutaneousWest Ward Pharmaceutical Corp.1971-01-01Not applicableUs
Morphine SulfateInjection8 mg/mLIntramuscular; Intravenous; SubcutaneousBaxter Healthcare Corporation2010-05-262015-12-29Us
Morphine SulfateInjection10 mg/mLIntramuscular; Intravenous; SubcutaneousWest Ward Pharmaceutical Corp.1971-01-01Not applicableUs
Morphine SulfateInjection, solution1 mg/mLIntravenousCantrell Drug Company2013-05-01Not applicableUs
Morphine SulfateInjection, solution30 mg/30mLIntravenous; SubcutaneousAmphastar Pharmaceuticals, Inc.1987-03-272016-12-06Us
Morphine SulfateSuppository20 mg/1RectalPaddock Laboratories, LLC1990-09-01Not applicableUs
Morphine SulfateInjection, solution2 mg/mLEpidural; Intramuscular; Intrathecal; IntravenousCantrell Drug Company2012-02-22Not applicableUs
Morphine SulfateInjection, solution, concentrate25 mg/mLIntravenousHospira, Inc.1996-03-14Not applicableUs
Morphine SulfateInjection15 mg/mLIntramuscular; Intravenous; SubcutaneousWest Ward Pharmaceutical Corp.1971-01-01Not applicableUs
Morphine SulfateInjection10 mg/mLIntramuscular; Intravenous; SubcutaneousBaxter Healthcare Corporation2010-05-262015-12-29Us
Morphine SulfateInjection, solution10 mg/10mLIntravenous; SubcutaneousAmphastar Pharmaceuticals, Inc.2000-08-112016-12-06Us
Morphine SulfateInjection, solution5 mg/mLIntravenousCantrell Drug Company2013-10-25Not applicableUs
Morphine SulfateSuppository30 mg/1RectalPaddock Laboratories, LLC1990-09-01Not applicableUs
Morphine SulfateInjection, solution25 mg/mLIntravenousHospira, Inc.1991-04-11Not applicableUs
Morphine SulfateInjection15 mg/mLIntramuscular; Intravenous; SubcutaneousWest Ward Pharmaceutical Corp.1971-01-01Not applicableUs
Morphine SulfateInjection15 mg/mLIntramuscular; Intravenous; SubcutaneousBaxter Healthcare Corporation2010-05-262015-12-29Us
Opium TinctureLiquid2 mg/5mLOralHi Tech Pharmacal Co., Inc.2012-08-06Not applicableUs
Opium Tincture DeodorizedSolution10 mg/mLOralValeant Pharmaceuticals North America LLC2008-09-17Not applicableUs
Opium Tincture DeodorizedTincture10 mg/mLOralEdenbridge Pharmaceuticals, LLC2010-07-15Not applicableUs
Opium Tincture DeodorizedSolution1 g/100mLOralANI Pharmaceuticals, Inc.2011-02-25Not applicableUs
Opium Tincture DeodorizedSolution10 mg/mLOralMarathon Pharmaceuticals, LLC2008-09-172016-08-10Us
International Brands
NameCompany
KapanolNot Available
MSIRNot Available
OramorphNot Available
RoxanolNot Available
Brand mixtures
NameLabellerIngredients
EmbedaSTAT Rx USA LLC
Salts
Name/CASStructureProperties
Morphine hydrochloride
52-26-6
Thumb
  • InChI Key: XCKKIKBIPZJUET-VYKNHSEDSA-N
  • Monoisotopic Mass: 321.1131712
  • Average Mass: 321.8
DBSALT001753
Morphine sulfate
64-31-3
Thumb
  • InChI Key: USAHOPJHPJHUNS-IFCNUISUSA-N
  • Monoisotopic Mass: 668.2403662
  • Average Mass: 668.754
DBSALT000122
Categories
UNII76I7G6D29C
CAS number57-27-2
WeightAverage: 285.3377
Monoisotopic: 285.136493479
Chemical FormulaC17H19NO3
InChI KeyBQJCRHHNABKAKU-KBQPJGBKSA-N
InChI
InChI=1S/C17H19NO3/c1-18-7-6-17-10-3-5-13(20)16(17)21-15-12(19)4-2-9(14(15)17)8-11(10)18/h2-5,10-11,13,16,19-20H,6-8H2,1H3/t10-,11+,13-,16-,17-/m0/s1
IUPAC Name
(1S,5R,13R,14S,17R)-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0¹,¹³.0⁵,¹⁷.0⁷,¹⁸]octadeca-7(18),8,10,15-tetraene-10,14-diol
SMILES
[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O
Pharmacology
IndicationFor the relief and treatment of severe pain.
Structured Indications
PharmacodynamicsMorphine is a narcotic pain management agent indicated for the relief of pain in patients who require opioid analgesics for more than a few days. Morphine interacts predominantly with the opioid mu-receptor. These mu-binding sites are discretely distributed in the human brain, with high densities in the posterior amygdala, hypothalamus, thalamus, nucleus caudatus, putamen, and certain cortical areas. They are also found on the terminal axons of primary afferents within laminae I and II (substantia gelatinosa) of the spinal cord and in the spinal nucleus of the trigeminal nerve. In clinical settings, morphine exerts its principal pharmacological effect on the central nervous system and gastrointestinal tract. Its primary actions of therapeutic value are analgesia and sedation. Morphine appears to increase the patient's tolerance for pain and to decrease discomfort, although the presence of the pain itself may still be recognized. In addition to analgesia, alterations in mood, euphoria and dysphoria, and drowsiness commonly occur. Opioids also produce respiratory depression by direct action on brain stem respiratory centers.
Mechanism of actionThe precise mechanism of the analgesic action of morphine is unknown. However, specific CNS opiate receptors have been identified and likely play a role in the expression of analgesic effects. Morphine first acts on the mu-opioid receptors. The mechanism of respiratory depression involves a reduction in the responsiveness of the brain stem respiratory centers to increases in carbon dioxide tension and to electrical stimulation. It has been shown that morphine binds to and inhibits GABA inhibitory interneurons. These interneurons normally inhibit the descending pain inhibition pathway. So, without the inhibitory signals, pain modulation can proceed downstream.
TargetKindPharmacological actionActionsOrganismUniProt ID
Mu-type opioid receptorProteinyes
agonist
HumanP35372 details
Kappa-type opioid receptorProteinyes
agonist
HumanP41145 details
Delta-type opioid receptorProteinyes
agonist
HumanP41143 details
Related Articles
AbsorptionBioavailability is approximately 30%.
Volume of distribution
  • 1 to 6 L/kg
Protein binding30-40%
Metabolism

Primarily hepatic (90%), converted to dihydromorphinone and normorphine. Also converted to morphine-3-glucuronide (M3G) and morphine-6-glucuronide. Virtually all morphine is converted to glucuronide metabolites; only a small fraction (less than 5%) of absorbed morphine is demethylated.

SubstrateEnzymesProduct
Morphine
morphine-6-glucuronideDetails
Morphine
morphine-3-glucuronideDetails
Morphine
Not Available
NormorphineDetails
Route of eliminationA small amount of glucuronide conjugates are excreted in bile, with minor enterohepatic recycling. Seven to 10% of administered morphine sulfate is excreted in the feces.
Half life2-4 hours
Clearance
  • 20 – 30 mL/min/kg [Adult]
  • 1852 +/- 116 mL/min [Chinese]
  • 1495 +/- 80 mL/min [Caucasian]
ToxicityLD50 = 461 mg/kg (rat, oral), 600 mg/kg (mouse, oral). Human lethal dose by ingestion is 120-250 mg of morphine sulfate. Symptoms of overdose include cold, clammy skin, flaccid muscles, fluid in the lungs, lowered blood pressure, "pinpoint" or dilated pupils, sleepiness leading to stupor and coma, slowed breathing, and slow pulse rate.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Codeine Action PathwayDrug actionSMP00405
Heroin Action PathwayDrug actionSMP00407
Heroin Metabolism PathwayDrug metabolismSMP00623
Morphine Action PathwayDrug actionSMP00406
Codeine Metabolism PathwayDrug metabolismSMP00621
Morphine Metabolism PathwayDrug metabolismSMP00622
SNP Mediated Effects
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeEffectReference(s)
Multidrug resistance protein 1
Gene symbol: ABCB1
UniProt: P08183
rs1045642 Not AvailableT AlleleBetter response to pain relief drugs17898703
Mu-type opioid receptor
Gene symbol: OPRM1
UniProt: P35372
rs1799971 Not AvailableA AlleleBetter response to pain relief drugs17898703
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Morphine is combined with 1,1,1,2 Tetrafluoroethane.Investigational
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Morphine.Experimental, Illicit
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Morphine.Experimental, Illicit
3,4-Methylenedioxymethamphetamine3,4-Methylenedioxymethamphetamine may increase the analgesic activities of Morphine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Morphine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Morphine is combined with 7-Nitroindazole.Experimental
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINEThe risk or severity of adverse effects can be increased when 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE is combined with Morphine.Experimental
AbirateroneThe serum concentration of Morphine can be increased when it is combined with Abiraterone.Approved
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Morphine.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Morphine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Morphine is combined with Aceprometazine.Approved
AcetaminophenThe serum concentration of Morphine can be increased when it is combined with Acetaminophen.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Morphine is combined with Acetazolamide.Approved, Vet Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Morphine.Approved, Vet Approved
AclidiniumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Morphine.Approved
adipiplonThe risk or severity of adverse effects can be increased when Morphine is combined with adipiplon.Investigational
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Morphine.Approved
AgomelatineThe risk or severity of adverse effects can be increased when Morphine is combined with Agomelatine.Approved, Investigational
AlbendazoleThe serum concentration of Morphine can be increased when it is combined with Albendazole.Approved, Vet Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Morphine.Approved
AldosteroneThe serum concentration of Morphine can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Morphine can be increased when it is combined with Alectinib.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Morphine is combined with Alfaxalone.Vet Approved
AlfentanilThe serum concentration of Morphine can be increased when it is combined with Alfentanil.Approved, Illicit
AlimemazineAlimemazine may increase the hypotensive activities of Morphine.Approved, Vet Approved
AliskirenThe risk or severity of adverse effects can be increased when Aliskiren is combined with Morphine.Approved, Investigational
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Morphine.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Morphine is combined with Alphacetylmethadol.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Morphine is combined with Alprazolam.Approved, Illicit, Investigational
AlvimopanThe risk or severity of adverse effects can be increased when Morphine is combined with Alvimopan.Approved
AmantadineThe serum concentration of Morphine can be increased when it is combined with Amantadine.Approved
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Morphine.Approved, Investigational
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Morphine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Morphine is combined with Amiloride.Approved
Aminohippuric acidThe serum concentration of Morphine can be increased when it is combined with Aminohippuric acid.Approved
AmiodaroneThe metabolism of Morphine can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Morphine is combined with Amisulpride.Approved, Investigational
AmitriptylineThe serum concentration of Morphine can be increased when it is combined with Amitriptyline.Approved
AmlodipineThe serum concentration of Morphine can be increased when it is combined with Amlodipine.Approved
Ammonium chlorideAmmonium chloride may increase the excretion rate of Morphine which could result in a lower serum level and potentially a reduction in efficacy.Approved, Vet Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Morphine is combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Morphine is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Morphine is combined with Amperozide.Experimental
AmphetamineAmphetamine may increase the analgesic activities of Morphine.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Morphine.Approved, Investigational
AmprenavirThe serum concentration of Morphine can be decreased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Morphine can be increased when it is combined with Amsacrine.Approved
Amyl NitriteThe risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Morphine.Approved
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Morphine.Approved
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Morphine.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Morphine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Morphine.Approved
AprepitantThe serum concentration of Morphine can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Morphine.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Morphine.Approved
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Morphine.Approved, Investigational
ArtemetherThe metabolism of Morphine can be decreased when combined with Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Morphine is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Morphine is combined with Asenapine.Approved
AstemizoleThe serum concentration of Morphine can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe metabolism of Morphine can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Morphine can be increased when it is combined with Atenolol.Approved
AtomoxetineThe metabolism of Morphine can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Morphine can be increased when it is combined with Atorvastatin.Approved
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Morphine.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Morphine.Approved, Vet Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Morphine.Approved, Investigational
AzaperoneThe risk or severity of adverse effects can be increased when Morphine is combined with Azaperone.Vet Approved
AzelastineMorphine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe serum concentration of Morphine can be increased when it is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Morphine.Approved
AzithromycinThe serum concentration of Morphine can be increased when it is combined with Azithromycin.Approved
AzosemideThe risk or severity of adverse effects can be increased when Morphine is combined with Azosemide.Investigational
BaclofenThe risk or severity of adverse effects can be increased when Morphine is combined with Baclofen.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Morphine.Experimental
BarbitalThe risk or severity of adverse effects can be increased when Morphine is combined with Barbital.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Morphine.Approved
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Morphine.Withdrawn
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Morphine.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Morphine is combined with Bendroflumethiazide.Approved
BenmoxinThe risk or severity of adverse effects can be increased when Benmoxin is combined with Morphine.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Morphine is combined with Benperidol.Investigational
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Morphine.Approved
BenzocaineThe serum concentration of Morphine can be increased when it is combined with Benzocaine.Approved
BenzphetamineBenzphetamine may increase the analgesic activities of Morphine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Morphine is combined with Benzyl alcohol.Approved
BepridilThe serum concentration of Morphine can be increased when it is combined with Bepridil.Approved, Withdrawn
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Morphine.Approved, Vet Approved
BetaxololThe metabolism of Morphine can be decreased when combined with Betaxolol.Approved
BexaroteneThe serum concentration of Morphine can be decreased when it is combined with Bexarotene.Approved, Investigational
BiperidenThe serum concentration of Morphine can be increased when it is combined with Biperiden.Approved
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Morphine.Approved
BL-1020BL-1020 may increase the hypotensive activities of Morphine.Investigational
BoceprevirThe metabolism of Morphine can be decreased when combined with Boceprevir.Approved
BortezomibThe metabolism of Morphine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Morphine can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Morphine.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Morphine.Approved
BretyliumThe risk or severity of adverse effects can be increased when Bretylium is combined with Morphine.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Morphine is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Morphine is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Morphine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Morphine is combined with Bromazepam.Approved, Illicit
BromocriptineThe serum concentration of Morphine can be increased when it is combined with Bromocriptine.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Morphine is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Morphine is combined with Brotizolam.Approved, Withdrawn
BumetanideThe risk or severity of adverse effects can be increased when Morphine is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Morphine is combined with Bupivacaine.Approved, Investigational
BuprenorphineMorphine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Morphine can be decreased when combined with Bupropion.Approved
BuspironeThe serum concentration of Morphine can be increased when it is combined with Buspirone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Morphine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Morphine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Morphine is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Morphine is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Morphine is combined with Butethal.Approved, Illicit
ButorphanolButorphanol may decrease the analgesic activities of Morphine.Approved, Illicit, Vet Approved
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Morphine.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Morphine.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Morphine.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Morphine.Approved
CandesartanThe serum concentration of Morphine can be increased when it is combined with Candesartan.Approved
Canrenoic acidThe risk or severity of adverse effects can be increased when Morphine is combined with Canrenoic acid.Approved, Withdrawn
CanrenoneThe risk or severity of adverse effects can be increased when Morphine is combined with Canrenone.Investigational
CaptoprilThe serum concentration of Morphine can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Morphine can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Morphine.Approved
CarbinoxamineThe risk or severity of adverse effects can be increased when Morphine is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Morphine is combined with Carfentanil.Illicit, Vet Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Morphine.Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Morphine is combined with Carisoprodol.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Caroxazone is combined with Morphine.Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Morphine.Approved
CarvedilolThe serum concentration of Morphine can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Morphine can be increased when it is combined with Caspofungin.Approved
CelecoxibThe metabolism of Morphine can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Morphine can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Morphine.Withdrawn
CetirizineThe risk or severity of adverse effects can be increased when Morphine is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Morphine is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Morphine is combined with Chlordiazepoxide.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Morphine is combined with Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Morphine is combined with Chloroprocaine.Approved
ChloroquineThe serum concentration of Morphine can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Morphine is combined with Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Morphine is combined with Chlorphenamine.Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Morphine.Withdrawn
ChlorphentermineChlorphentermine may increase the analgesic activities of Morphine.Illicit, Withdrawn
ChlorpromazineThe serum concentration of Morphine can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Morphine can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Morphine can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Morphine is combined with Chlorthalidone.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Morphine is combined with Chlorzoxazone.Approved
CholecalciferolThe metabolism of Morphine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholesterolThe serum concentration of Morphine can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Morphine can be decreased when it is combined with Cholic Acid.Approved
CicletanineThe risk or severity of adverse effects can be increased when Morphine is combined with Cicletanine.Investigational
CilazaprilThe serum concentration of Morphine can be increased when it is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Morphine.Approved
CimetidineThe serum concentration of Morphine can be decreased when it is combined with Cimetidine.Approved
CinacalcetThe metabolism of Morphine can be decreased when combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Morphine is combined with Cinchocaine.Approved, Vet Approved
CiprofloxacinThe serum concentration of Morphine can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Morphine.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Morphine.Approved
ClarithromycinThe metabolism of Morphine can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Morphine can be decreased when combined with Clemastine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Morphine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Morphine is combined with Clidinium.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Morphine.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Morphine.Approved, Investigational
ClofazimineThe serum concentration of Morphine can be increased when it is combined with Clofazimine.Approved, Investigational
clomethiazoleThe risk or severity of adverse effects can be increased when Morphine is combined with clomethiazole.Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Morphine.Approved, Investigational
ClomipramineThe serum concentration of Morphine can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Morphine is combined with Clonazepam.Approved, Illicit
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Morphine.Approved
ClopidogrelMorphine may decrease the antiplatelet activities of Clopidogrel.Approved, Nutraceutical
ClopidogrelThe metabolism of Morphine can be decreased when combined with Clopidogrel.Approved, Nutraceutical
ClorazepateThe risk or severity of adverse effects can be increased when Morphine is combined with Clorazepate.Approved, Illicit
ClotrimazoleThe metabolism of Morphine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Morphine.Approved
CobicistatThe serum concentration of Morphine can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Morphine.Approved
CocaineThe metabolism of Morphine can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Morphine is combined with Codeine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Morphine.Approved
ColforsinThe serum concentration of Morphine can be increased when it is combined with Colforsin.Experimental
ConivaptanThe serum concentration of Morphine can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Morphine.Approved
CrizotinibThe metabolism of Morphine can be decreased when combined with Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Morphine is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Morphine is combined with Cyclobenzaprine.Approved
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Morphine.Approved
CyclophosphamideThe serum concentration of Morphine can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe metabolism of Morphine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideThe risk or severity of adverse effects can be increased when Morphine is combined with Cyclothiazide.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Morphine is combined with Cyproheptadine.Approved
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Morphine.Approved
DabrafenibThe serum concentration of Morphine can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Morphine can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Morphine can be increased when it is combined with Dactinomycin.Approved
DantroleneThe risk or severity of adverse effects can be increased when Morphine is combined with Dantrolene.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Morphine.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Morphine is combined with Dapiprazole.Approved
DapoxetineMorphine may increase the serotonergic activities of Dapoxetine.Investigational
DarifenacinThe metabolism of Morphine can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Morphine can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Morphine can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Morphine can be decreased when it is combined with Daunorubicin.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Morphine.Approved
DeferasiroxThe serum concentration of Morphine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Morphine can be decreased when combined with Delavirdine.Approved
deramciclaneThe risk or severity of adverse effects can be increased when Morphine is combined with deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Morphine is combined with Desflurane.Approved
DesipramineThe serum concentration of Morphine can be increased when it is combined with Desipramine.Approved
DesloratadineThe serum concentration of Morphine can be increased when it is combined with Desloratadine.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Morphine is combined with Desmopressin.Approved
DesvenlafaxineMorphine may increase the serotonergic activities of Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Morphine is combined with Detomidine.Vet Approved
DexamethasoneThe serum concentration of Morphine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Morphine is combined with Dexbrompheniramine.Approved
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Morphine.Withdrawn
DexmedetomidineThe risk or severity of adverse effects can be increased when Morphine is combined with Dexmedetomidine.Approved, Vet Approved
DextroamphetamineDextroamphetamine may increase the analgesic activities of Morphine.Approved, Illicit
DextromethorphanThe serum concentration of Morphine can be increased when it is combined with Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Morphine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Morphine is combined with Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Morphine is combined with Dezocine.Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Morphine.Approved, Illicit, Vet Approved
DiclofenacThe serum concentration of Morphine can be increased when it is combined with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Morphine.Approved
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Morphine.Approved
DiethylpropionDiethylpropion may increase the analgesic activities of Morphine.Approved, Illicit
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Morphine.Approved
DifenoxinThe risk or severity of adverse effects can be increased when Morphine is combined with Difenoxin.Approved, Illicit
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Morphine.Approved
DigoxinThe serum concentration of Morphine can be decreased when it is combined with Digoxin.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Morphine is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineThe metabolism of Morphine can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Dihydromorphine.Experimental, Illicit
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Morphine.Illicit
DiltiazemThe metabolism of Morphine can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Morphine is combined with Dimenhydrinate.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Morphine.Approved
DiphenhydramineThe metabolism of Morphine can be decreased when combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Morphine is combined with Diphenoxylate.Approved, Illicit
DipyridamoleThe serum concentration of Morphine can be increased when it is combined with Dipyridamole.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Morphine.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Morphine.Approved, Investigational, Vet Approved
DoramectinThe risk or severity of adverse effects can be increased when Morphine is combined with Doramectin.Vet Approved
DoxazosinThe serum concentration of Morphine can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Morphine can be increased when it is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Morphine.Approved, Investigational
DoxorubicinThe serum concentration of Morphine can be decreased when it is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Morphine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Morphine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Morphine is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Morphine.Approved, Illicit
DronedaroneThe metabolism of Morphine can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Morphine.Approved, Vet Approved
DrospirenoneThe risk or severity of adverse effects can be increased when Morphine is combined with Drospirenone.Approved
DrotebanolThe risk or severity of adverse effects can be increased when Morphine is combined with Drotebanol.Experimental, Illicit
DuloxetineMorphine may increase the orthostatic hypotensive activities of Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Morphine is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Morphine is combined with Ecgonine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Morphine is combined with ECGONINE METHYL ESTER.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Morphine is combined with Ecopipam.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Morphine.Approved
EfavirenzThe serum concentration of Morphine can be decreased when it is combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Morphine is combined with Efonidipine.Approved
ElbasvirThe serum concentration of Morphine can be increased when it is combined with Elbasvir.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Morphine.Approved, Investigational
EliglustatThe metabolism of Morphine can be decreased when combined with Eliglustat.Approved
EluxadolineMorphine may increase the constipating activities of Eluxadoline.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Morphine.Approved
EnalaprilThe serum concentration of Morphine can be increased when it is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Morphine.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Morphine.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Morphine is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Morphine can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Morphine.Approved, Investigational
EplerenoneThe risk or severity of adverse effects can be increased when Morphine is combined with Eplerenone.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Morphine.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Morphine.Approved
ErgonovineThe serum concentration of Morphine can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Morphine can be increased when it is combined with Ergotamine.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Morphine.Approved, Investigational
ErythromycinThe metabolism of Morphine can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramMorphine may increase the serotonergic activities of Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Morphine can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Morphine.Approved
EstazolamThe risk or severity of adverse effects can be increased when Morphine is combined with Estazolam.Approved, Illicit
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Morphine.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Morphine can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Morphine can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Morphine can be decreased when it is combined with Estrone.Approved
EszopicloneThe risk or severity of adverse effects can be increased when Morphine is combined with Eszopiclone.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Morphine is combined with Etacrynic acid.Approved
EthanolMorphine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Morphine.Approved, Illicit, Withdrawn
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Morphine.Approved
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Morphine.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Morphine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Morphine is combined with Ethotoin.Approved
EthoxzolamideThe risk or severity of adverse effects can be increased when Morphine is combined with Ethoxzolamide.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Morphine is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Morphine is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Morphine is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Morphine is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Morphine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Morphine.Approved
EtoperidoneMorphine may increase the serotonergic activities of Etoperidone.Approved
EtoposideThe serum concentration of Morphine can be increased when it is combined with Etoposide.Approved
EtorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Etorphine.Illicit, Vet Approved
EtravirineThe serum concentration of Morphine can be decreased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Morphine.Approved
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Morphine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Morphine is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Morphine is combined with Felbamate.Approved
FelodipineThe serum concentration of Morphine can be increased when it is combined with Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Morphine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenoldopamThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Morphine.Approved
FentanylThe serum concentration of Morphine can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Morphine.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Morphine.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Morphine.Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Morphine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Morphine is combined with Flibanserin.Approved
FluconazoleThe metabolism of Morphine can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Morphine is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Morphine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Morphine is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe metabolism of Morphine can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Morphine can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Morphine can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Morphine can be increased when it is combined with Flurazepam.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Morphine is combined with Fluspirilene.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Morphine.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Morphine is combined with Fluticasone Propionate.Approved
FluvoxamineThe metabolism of Morphine can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Morphine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Morphine can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Morphine.Approved
FosphenytoinThe metabolism of Morphine can be increased when combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Morphine is combined with Fospropofol.Approved, Illicit
FurazolidoneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Morphine.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Morphine is combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Morphine can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Morphine is combined with Gabapentin.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Morphine is combined with gabapentin enacarbil.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Morphine.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Morphine is combined with Gamma Hydroxybutyric Acid.Approved, Illicit
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Morphine.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Morphine.Approved
GemfibrozilThe metabolism of Morphine can be decreased when combined with Gemfibrozil.Approved
GenisteinThe serum concentration of Morphine can be increased when it is combined with Genistein.Investigational
GepironeThe risk or severity of adverse effects can be increased when Morphine is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Morphine is combined with Glutethimide.Approved, Illicit
GlyburideThe serum concentration of Morphine can be increased when it is combined with Glyburide.Approved
GlycerolThe serum concentration of Morphine can be increased when it is combined with Glycerol.Experimental
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Morphine.Approved, Investigational, Vet Approved
Gramicidin DThe serum concentration of Morphine can be increased when it is combined with Gramicidin D.Approved
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Morphine.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Morphine.Withdrawn
GuanfacineThe risk or severity of adverse effects can be increased when Morphine is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Morphine is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe serum concentration of Morphine can be increased when it is combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Morphine is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Morphine is combined with Heroin.Approved, Illicit
HexamethoniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Morphine.Experimental
HexobarbitalThe risk or severity of adverse effects can be increased when Morphine is combined with Hexobarbital.Approved
HomatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with Morphine.Approved
HydracarbazineThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Morphine.Approved
HydralazineThe risk or severity of adverse effects can be increased when Hydralazine is combined with Morphine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Morphine is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneMorphine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Morphine.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Morphine is combined with Hydroflumethiazide.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Morphine is combined with Hydromorphone.Approved, Illicit
Hydroxyamphetamine hydrobromideHydroxyamphetamine hydrobromide may increase the analgesic activities of Morphine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Morphine.Approved
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Morphine.Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Morphine.Approved
IdelalisibThe serum concentration of Morphine can be increased when it is combined with Idelalisib.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Morphine is combined with Iloperidone.Approved
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Morphine.Approved, Investigational
ImatinibThe metabolism of Morphine can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Morphine.Investigational
ImipramineThe serum concentration of Morphine can be increased when it is combined with Imipramine.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Morphine.Approved
IndalpineMorphine may increase the serotonergic activities of Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Morphine is combined with Indapamide.Approved
IndinavirThe metabolism of Morphine can be decreased when combined with Indinavir.Approved
IndomethacinThe serum concentration of Morphine can be increased when it is combined with Indomethacin.Approved, Investigational
IndoraminThe risk or severity of adverse effects can be increased when Indoramin is combined with Morphine.Withdrawn
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Morphine.Approved
IproclozideThe risk or severity of adverse effects can be increased when Iproclozide is combined with Morphine.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Iproniazid is combined with Morphine.Withdrawn
IrbesartanThe metabolism of Morphine can be decreased when combined with Irbesartan.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Morphine.Approved, Investigational
IsavuconazoniumThe metabolism of Morphine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Morphine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Morphine is combined with Isoflurane.Approved, Vet Approved
IsoniazidThe metabolism of Morphine can be decreased when combined with Isoniazid.Approved
IsosorbideThe risk or severity of adverse effects can be increased when Morphine is combined with Isosorbide.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Morphine.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Morphine.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Isoxsuprine is combined with Morphine.Approved, Withdrawn
IsradipineThe metabolism of Morphine can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Morphine can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Morphine can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Morphine.Approved, Vet Approved
KetamineThe serum concentration of Morphine can be increased when it is combined with Ketamine.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Morphine.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Morphine is combined with Ketobemidone.Approved
KetoconazoleThe metabolism of Morphine can be decreased when combined with Ketoconazole.Approved, Investigational
KW-3902The risk or severity of adverse effects can be increased when Morphine is combined with KW-3902.Investigational
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Morphine.Approved
LacidipineThe risk or severity of adverse effects can be increased when Lacidipine is combined with Morphine.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Morphine.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Morphine.Approved, Investigational
LansoprazoleThe serum concentration of Morphine can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Morphine can be increased when it is combined with Lapatinib.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Morphine.Approved
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Morphine.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Morphine.Approved
LercanidipineThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Morphine.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Morphine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Levobunolol is combined with Morphine.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Morphine is combined with Levobupivacaine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Morphine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Morphine is combined with Levocetirizine.Approved
LevodopaMorphine may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Morphine.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Morphine is combined with Levomethadyl Acetate.Approved
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Morphine.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Morphine is combined with Levorphanol.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Morphine.Approved, Investigational
LevothyroxineThe serum concentration of Morphine can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Morphine can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Morphine.Approved
LiothyronineThe serum concentration of Morphine can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Morphine can be decreased when it is combined with Liotrix.Approved
LisdexamfetamineLisdexamfetamine may increase the analgesic activities of Morphine.Approved, Investigational
LisinoprilThe serum concentration of Morphine can be increased when it is combined with Lisinopril.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Morphine is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Morphine is combined with Lofentanil.Illicit
LofexidineThe risk or severity of adverse effects can be increased when Lofexidine is combined with Morphine.Approved, Investigational
LomitapideThe serum concentration of Morphine can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Morphine can be increased when it is combined with Loperamide.Approved
LopinavirThe metabolism of Morphine can be decreased when combined with Lopinavir.Approved
LoratadineThe serum concentration of Morphine can be increased when it is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Morphine.Approved
LorcaserinThe metabolism of Morphine can be decreased when combined with Lorcaserin.Approved
LosartanThe serum concentration of Morphine can be increased when it is combined with Losartan.Approved
LovastatinThe metabolism of Morphine can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Morphine is combined with Loxapine.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Morphine is combined with Lu AA21004.Investigational
LuliconazoleThe serum concentration of Morphine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Morphine can be increased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Morphine can be decreased when combined with Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Morphine is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Morphine.Approved, Vet Approved
MannitolThe risk or severity of adverse effects can be increased when Morphine is combined with Mannitol.Approved, Investigational
MaprotilineThe serum concentration of Morphine can be increased when it is combined with Maprotiline.Approved
MebanazineThe risk or severity of adverse effects can be increased when Mebanazine is combined with Morphine.Withdrawn
MebendazoleThe serum concentration of Morphine can be increased when it is combined with Mebendazole.Approved, Vet Approved
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Morphine.Approved
MeclizineThe risk or severity of adverse effects can be increased when Morphine is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Morphine is combined with Medetomidine.Vet Approved
MefloquineThe serum concentration of Morphine can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe serum concentration of Morphine can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Morphine is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Morphine is combined with Melperone.Approved
MephedroneMephedrone may increase the analgesic activities of Morphine.Investigational
MephentermineMephentermine may increase the analgesic activities of Morphine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Morphine is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe serum concentration of Morphine can be increased when it is combined with Meprobamate.Approved, Illicit
MersalylThe risk or severity of adverse effects can be increased when Morphine is combined with Mersalyl.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Morphine is combined with Mesoridazine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Morphine is combined with Metaxalone.Approved
MethadoneThe serum concentration of Morphine can be increased when it is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Morphine is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineMethamphetamine may increase the analgesic activities of Morphine.Approved, Illicit
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Morphine.Approved
MethapyrileneThe risk or severity of adverse effects can be increased when Morphine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Morphine is combined with Methaqualone.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Morphine is combined with Methazolamide.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Morphine is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Morphine is combined with Methohexital.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Morphine.Approved
MethotrimeprazineMorphine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Morphine is combined with Methoxyflurane.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Morphine is combined with Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Morphine is combined with Methyclothiazide.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Morphine.Approved
Methylene blueThe risk or severity of adverse effects can be increased when Methylene blue is combined with Morphine.Investigational
Methylene blueMethylene blue may increase the hypotensive activities of Morphine.Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Morphine is combined with Methylphenobarbital.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Morphine.Approved, Vet Approved
MetipranololThe risk or severity of adverse effects can be increased when Metipranolol is combined with Morphine.Approved
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with Morphine.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Morphine is combined with Metolazone.Approved
MetoprololThe serum concentration of Morphine can be increased when it is combined with Metoprolol.Approved, Investigational
MetyrosineMorphine may increase the sedative activities of Metyrosine.Approved
MibefradilThe serum concentration of Morphine can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Morphine can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Morphine can be decreased when it is combined with Midazolam.Approved, Illicit
MifepristoneThe serum concentration of Morphine can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranMorphine may increase the serotonergic activities of Milnacipran.Approved
MinaprineThe risk or severity of adverse effects can be increased when Minaprine is combined with Morphine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Morphine.Approved, Investigational
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Morphine.Approved
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Morphine.Approved
MirtazapineMorphine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitomycinThe serum concentration of Morphine can be increased when it is combined with Mitomycin.Approved
MitotaneThe serum concentration of Morphine can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Morphine can be decreased when it is combined with Mitoxantrone.Approved, Investigational
MMDAMMDA may increase the analgesic activities of Morphine.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Morphine.Approved
ModafinilThe serum concentration of Morphine can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Morphine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Morphine is combined with Molindone.Approved
MoricizineMoricizine may increase the hypotensive activities of Morphine.Approved, Withdrawn
MoxonidineThe risk or severity of adverse effects can be increased when Morphine is combined with Moxonidine.Approved
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Morphine.Approved, Investigational
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when N-butylscopolammonium bromide is combined with Morphine.Vet Approved
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Morphine.Approved, Investigational
NadololThe serum concentration of Nadolol can be increased when it is combined with Morphine.Approved
NafcillinThe serum concentration of Morphine can be decreased when it is combined with Nafcillin.Approved
NalbuphineNalbuphine may decrease the analgesic activities of Morphine.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Morphine.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Morphine.Approved, Vet Approved
NaltrexoneThe therapeutic efficacy of Morphine can be decreased when used in combination with Naltrexone.Approved, Investigational, Vet Approved
NaringeninThe serum concentration of Morphine can be increased when it is combined with Naringenin.Experimental
NebivololThe risk or severity of adverse effects can be increased when Nebivolol is combined with Morphine.Approved, Investigational
NefazodoneThe metabolism of Morphine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Morphine can be decreased when combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Morphine can be increased when it is combined with Neostigmine.Approved, Vet Approved
NesiritideThe risk or severity of adverse effects can be increased when Nesiritide is combined with Morphine.Approved, Investigational
NetupitantThe serum concentration of Morphine can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Morphine can be increased when combined with Nevirapine.Approved
NialamideThe risk or severity of adverse effects can be increased when Nialamide is combined with Morphine.Withdrawn
NicardipineThe serum concentration of Morphine can be increased when it is combined with Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Morphine.Approved
NifedipineThe serum concentration of Morphine can be decreased when it is combined with Nifedipine.Approved
NilotinibThe metabolism of Morphine can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineThe risk or severity of adverse effects can be increased when Morphine is combined with Nilvadipine.Approved
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Morphine.Approved
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Morphine.Approved
NisoldipineThe serum concentration of Morphine can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Morphine can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Morphine can be increased when it is combined with Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Morphine is combined with Nitric Oxide.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Morphine.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Morphine.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Morphine is combined with Nitrous oxide.Approved, Vet Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Morphine.Approved
NorethisteroneThe serum concentration of Morphine can be decreased when it is combined with Norethisterone.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Morphine is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Morphine is combined with Nortriptyline.Approved
NVA237The risk or severity of adverse effects can be increased when NVA237 is combined with Morphine.Investigational
ObinutuzumabThe risk or severity of adverse effects can be increased when Morphine is combined with Obinutuzumab.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Octamoxin is combined with Morphine.Withdrawn
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Morphine.Approved, Investigational
OlaparibThe metabolism of Morphine can be decreased when combined with Olaparib.Approved
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Morphine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Morphine is combined with Olopatadine.Approved
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Morphine.Approved
OmeprazoleThe serum concentration of Morphine can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronThe risk or severity of adverse effects can be increased when Morphine is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Morphine is combined with Opium.Approved, Illicit
OrphenadrineMorphine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Morphine is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Morphine can be increased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Morphine is combined with Oxazepam.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Morphine is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Morphine is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Morphine is combined with Oxybuprocaine.Approved
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Morphine.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Morphine is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Morphine is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Morphine.Approved
P-NitrophenolThe serum concentration of Morphine can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe serum concentration of Morphine can be increased when it is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Morphine can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Morphine is combined with Paliperidone.Approved
Palmitic AcidThe serum concentration of Morphine can be increased when it is combined with Palmitic Acid.Experimental
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Morphine.Approved
PanobinostatThe serum concentration of Morphine can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe serum concentration of Morphine can be increased when it is combined with Pantoprazole.Approved
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Morphine.Approved
ParaldehydeMorphine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
PargylineThe risk or severity of adverse effects can be increased when Pargyline is combined with Morphine.Approved
ParoxetineThe metabolism of Morphine can be decreased when combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Morphine.Approved
Peginterferon alfa-2bThe serum concentration of Morphine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PegvisomantThe therapeutic efficacy of Pegvisomant can be decreased when used in combination with Morphine.Approved
PenbutololThe risk or severity of adverse effects can be increased when Penbutolol is combined with Morphine.Approved, Investigational
PentazocinePentazocine may decrease the analgesic activities of Morphine.Approved, Vet Approved
PentobarbitalThe metabolism of Morphine can be increased when combined with Pentobarbital.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Morphine.Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Morphine.Approved
PerazineThe risk or severity of adverse effects can be increased when Morphine is combined with Perazine.Investigational
PerindoprilThe serum concentration of Morphine can be increased when it is combined with Perindopril.Approved
PerospironeThe risk or severity of adverse effects can be increased when Morphine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Morphine is combined with Perphenazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Morphine is combined with Pethidine.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Morphine.Approved
PheniprazineThe risk or severity of adverse effects can be increased when Pheniprazine is combined with Morphine.Withdrawn
PhenobarbitalThe metabolism of Morphine can be increased when combined with Phenobarbital.Approved
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Morphine is combined with Phenoxybenzamine.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Morphine is combined with Phenoxyethanol.Approved
PhenoxypropazineThe risk or severity of adverse effects can be increased when Phenoxypropazine is combined with Morphine.Withdrawn
PhenterminePhentermine may increase the analgesic activities of Morphine.Approved, Illicit
PhentolamineThe risk or severity of adverse effects can be increased when Morphine is combined with Phentolamine.Approved
PhenytoinThe metabolism of Morphine can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideThe serum concentration of Morphine can be increased when it is combined with Pimozide.Approved
PindololThe risk or severity of adverse effects can be increased when Pindolol is combined with Morphine.Approved
PioglitazoneThe metabolism of Morphine can be decreased when combined with Pioglitazone.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Morphine is combined with Pipamperone.Approved
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Morphine.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Morphine is combined with Pipotiazine.Approved
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Morphine.Approved
PiretanideThe risk or severity of adverse effects can be increased when Morphine is combined with Piretanide.Experimental
PiritramideThe risk or severity of adverse effects can be increased when Morphine is combined with Piritramide.Investigational
PirlindoleThe risk or severity of adverse effects can be increased when Pirlindole is combined with Morphine.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Morphine.Approved
PivhydrazineThe risk or severity of adverse effects can be increased when Pivhydrazine is combined with Morphine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Morphine is combined with Pizotifen.Approved
Platelet Activating FactorThe serum concentration of Morphine can be decreased when it is combined with Platelet Activating Factor.Experimental
PolythiazideThe risk or severity of adverse effects can be increased when Morphine is combined with Polythiazide.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Morphine.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Morphine.Approved
PosaconazoleThe metabolism of Morphine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PotassiumThe risk or severity of adverse effects can be increased when Morphine is combined with Potassium.Approved
Potassium CitrateThe risk or severity of adverse effects can be increased when Morphine is combined with Potassium Citrate.Approved, Vet Approved
PramipexoleMorphine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Morphine is combined with Pramocaine.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Morphine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Morphine is combined with Prazepam.Approved, Illicit
PrazosinThe serum concentration of Morphine can be increased when it is combined with Prazosin.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Morphine.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Morphine.Approved, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Morphine.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Morphine is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Morphine is combined with Prilocaine.Approved
PrimidoneThe metabolism of Morphine can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Morphine can be increased when it is combined with Probenecid.Approved
ProcaineThe risk or severity of adverse effects can be increased when Morphine is combined with Procaine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Morphine is combined with Prochlorperazine.Approved, Vet Approved
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Morphine.Approved
ProgesteroneThe serum concentration of Morphine can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromazineThe metabolism of Morphine can be decreased when combined with Promazine.Approved, Vet Approved
PromethazineThe serum concentration of Morphine can be increased when it is combined with Promethazine.Approved
PropafenoneThe serum concentration of Morphine can be increased when it is combined with Propafenone.Approved
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Morphine.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Morphine is combined with Proparacaine.Approved, Vet Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Morphine.Vet Approved
PropiverineThe risk or severity of adverse effects can be increased when Propiverine is combined with Morphine.Investigational
PropofolThe risk or severity of adverse effects can be increased when Morphine is combined with Propofol.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Morphine is combined with Propoxycaine.Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Morphine.Approved, Investigational
ProtriptylineThe serum concentration of Morphine can be increased when it is combined with Protriptyline.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Morphine.Approved
PSD502The risk or severity of adverse effects can be increased when Morphine is combined with PSD502.Investigational
PseudoephedrinePseudoephedrine may increase the analgesic activities of Morphine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Morphine is combined with Quazepam.Approved, Illicit
QuercetinThe serum concentration of Morphine can be increased when it is combined with Quercetin.Experimental
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Morphine.Approved
QuinacrineThe serum concentration of Morphine can be increased when it is combined with Quinacrine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Morphine.Approved, Investigational
QuinethazoneThe risk or severity of adverse effects can be increased when Morphine is combined with Quinethazone.Approved
QuinidineThe metabolism of Morphine can be decreased when combined with Quinidine.Approved
QuinineThe serum concentration of Morphine can be increased when it is combined with Quinine.Approved
RabeprazoleThe metabolism of Morphine can be decreased when combined with Rabeprazole.Approved, Investigational
RacloprideThe risk or severity of adverse effects can be increased when Morphine is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Morphine is combined with Ramelteon.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Morphine.Approved
RamosetronMorphine may increase the constipating activities of Ramosetron.Approved
RanitidineThe serum concentration of Morphine can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Morphine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Morphine.Approved
ReboxetineThe serum concentration of Morphine can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Morphine can be increased when it is combined with Regorafenib.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Morphine is combined with Remifentanil.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Morphine is combined with Remoxipride.Approved, Withdrawn
ReserpineThe serum concentration of Morphine can be decreased when it is combined with Reserpine.Approved
RifabutinThe metabolism of Morphine can be increased when combined with Rifabutin.Approved
RifabutinThe serum concentration of Morphine can be decreased when it is combined with Rifabutin.Approved
RifampicinThe metabolism of Morphine can be increased when combined with Rifampicin.Approved
RifampicinThe serum concentration of Morphine can be decreased when it is combined with Rifampicin.Approved
RifapentineThe metabolism of Morphine can be increased when combined with Rifapentine.Approved
RifapentineThe serum concentration of Morphine can be decreased when it is combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Morphine.Approved, Investigational
RilpivirineThe serum concentration of Morphine can be increased when it is combined with Rilpivirine.Approved
RiociguatThe risk or severity of adverse effects can be increased when Riociguat is combined with Morphine.Approved
RisperidoneMorphine may increase the hypotensive activities of Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Morphine is combined with Ritanserin.Investigational
RitobegronRitobegron may increase the analgesic activities of Morphine.Investigational
RitonavirThe metabolism of Morphine can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Morphine.Approved
RolapitantThe serum concentration of Morphine can be increased when it is combined with Rolapitant.Approved
RolofyllineThe risk or severity of adverse effects can be increased when Morphine is combined with Rolofylline.Investigational
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Morphine.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Morphine is combined with Romifidine.Vet Approved
RopiniroleMorphine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Morphine is combined with Ropivacaine.Approved
RosiglitazoneThe metabolism of Morphine can be decreased when combined with Rosiglitazone.Approved, Investigational
RotigotineMorphine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Morphine.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Morphine is combined with S-Ethylisothiourea.Experimental
SacubitrilThe risk or severity of adverse effects can be increased when Morphine is combined with Sacubitril.Approved
SafrazineThe risk or severity of adverse effects can be increased when Safrazine is combined with Morphine.Withdrawn
Sage 547The risk or severity of adverse effects can be increased when Morphine is combined with Sage 547.Investigational
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Morphine.Approved, Vet Approved
SaquinavirThe metabolism of Morphine can be decreased when combined with Saquinavir.Approved, Investigational
ScopolamineThe serum concentration of Morphine can be increased when it is combined with Scopolamine.Approved
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Morphine.Approved
SecobarbitalThe metabolism of Morphine can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Morphine.Approved, Investigational, Vet Approved
SelegilineThe serum concentration of Morphine can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Morphine.Approved
SertindoleThe risk or severity of adverse effects can be increased when Morphine is combined with Sertindole.Approved, Withdrawn
SertralineThe serum concentration of Morphine can be increased when it is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Morphine is combined with Sevoflurane.Approved, Vet Approved
SildenafilThe metabolism of Morphine can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Morphine.Approved
SiltuximabThe serum concentration of Morphine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Morphine can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Morphine can be increased when it is combined with Simvastatin.Approved
SirolimusThe serum concentration of Morphine can be decreased when it is combined with Sirolimus.Approved, Investigational
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Morphine.Approved, Investigational
Sodium NitriteThe risk or severity of adverse effects can be increased when Morphine is combined with Sodium Nitrite.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Morphine.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Morphine.Approved
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Morphine.Approved
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Morphine.Approved, Investigational
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Morphine.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Morphine.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Morphine.Experimental
SpironolactoneThe risk or severity of adverse effects can be increased when Morphine is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Morphine can be decreased when it is combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Morphine can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Morphine can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Morphine is combined with Streptokinase.Approved
StreptozocinThe serum concentration of Morphine can be decreased when it is combined with Streptozocin.Approved
SuccinylcholineSuccinylcholine may increase the bradycardic activities of Morphine.Approved
SufentanilThe risk or severity of adverse effects can be increased when Morphine is combined with Sufentanil.Approved, Investigational
SulfamethoxazoleThe metabolism of Morphine can be decreased when combined with Sulfamethoxazole.Approved
SulfinpyrazoneThe serum concentration of Morphine can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe metabolism of Morphine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Morphine is combined with Sulpiride.Approved
SumatriptanThe serum concentration of Morphine can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Morphine can be increased when it is combined with Sunitinib.Approved, Investigational
SuvorexantMorphine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TacrineThe serum concentration of Morphine can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe serum concentration of Morphine can be decreased when it is combined with Tacrolimus.Approved, Investigational
TamoxifenThe serum concentration of Morphine can be decreased when it is combined with Tamoxifen.Approved
TamsulosinThe risk or severity of adverse effects can be increased when Morphine is combined with Tamsulosin.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Morphine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Morphine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Morphine is combined with Tasimelteon.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Morphine.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Morphine.Approved
TelaprevirThe metabolism of Morphine can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Morphine can be decreased when combined with Telithromycin.Approved
TelmisartanThe serum concentration of Morphine can be increased when it is combined with Telmisartan.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Morphine.Approved
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Morphine.Approved
TerazosinThe serum concentration of Morphine can be increased when it is combined with Terazosin.Approved
TerbinafineThe metabolism of Morphine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerfenadineThe serum concentration of Morphine can be increased when it is combined with Terfenadine.Withdrawn
TeriflunomideThe metabolism of Morphine can be decreased when combined with Teriflunomide.Approved
TesmilifeneThe serum concentration of Morphine can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Morphine can be increased when it is combined with Testosterone.Approved, Investigational
TetrabenazineThe risk or severity of adverse effects can be increased when Morphine is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Morphine is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Morphine is combined with Tetrodotoxin.Investigational
ThalidomideMorphine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheobromineThe risk or severity of adverse effects can be increased when Morphine is combined with Theobromine.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Morphine is combined with Thiamylal.Approved, Vet Approved
ThiethylperazineThiethylperazine may increase the hypotensive activities of Morphine.Withdrawn
ThiopentalThe risk or severity of adverse effects can be increased when Morphine is combined with Thiopental.Approved, Vet Approved
ThioridazineThe metabolism of Morphine can be decreased when combined with Thioridazine.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Morphine is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Morphine is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Morphine is combined with Tiapride.Investigational
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Morphine.Approved
TiclopidineThe metabolism of Morphine can be decreased when combined with Ticlopidine.Approved
TicrynafenThe risk or severity of adverse effects can be increased when Morphine is combined with Ticrynafen.Withdrawn
TiletamineThe risk or severity of adverse effects can be increased when Morphine is combined with Tiletamine.Vet Approved
TimololThe serum concentration of Timolol can be increased when it is combined with Morphine.Approved
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Morphine.Approved
TipranavirThe metabolism of Morphine can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Morphine is combined with Tizanidine.Approved
TocilizumabThe serum concentration of Morphine can be decreased when it is combined with Tocilizumab.Approved
TolazolineThe risk or severity of adverse effects can be increased when Morphine is combined with Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Morphine is combined with Tolcapone.Approved, Withdrawn
ToloxatoneThe risk or severity of adverse effects can be increased when Toloxatone is combined with Morphine.Approved
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Morphine.Approved, Investigational
TolvaptanThe risk or severity of adverse effects can be increased when Morphine is combined with Tolvaptan.Approved
TopiramateThe risk or severity of adverse effects can be increased when Morphine is combined with Topiramate.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Morphine.Approved, Investigational
TorasemideThe risk or severity of adverse effects can be increased when Morphine is combined with Torasemide.Approved
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Morphine.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Morphine.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Morphine.Approved
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Morphine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Morphine.Approved
TranylcypromineThe metabolism of Morphine can be decreased when combined with Tranylcypromine.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Morphine.Approved
TrazodoneThe serum concentration of Morphine can be decreased when it is combined with Trazodone.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Morphine is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Morphine is combined with Triamterene.Approved
TriazolamThe risk or severity of adverse effects can be increased when Morphine is combined with Triazolam.Approved
TrichlormethiazideThe risk or severity of adverse effects can be increased when Morphine is combined with Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe serum concentration of Morphine can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Morphine can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Morphine.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Morphine.Approved
TrimethoprimThe serum concentration of Morphine can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Morphine can be increased when it is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Morphine is combined with Triprolidine.Approved
TroleandomycinThe serum concentration of Morphine can be increased when it is combined with Troleandomycin.Approved
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Morphine.Approved
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Morphine.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Morphine.Approved
Uc1010The risk or severity of adverse effects can be increased when Morphine is combined with Uc1010.Investigational
UlaritideThe risk or severity of adverse effects can be increased when Morphine is combined with Ularitide.Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Morphine.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Morphine.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Morphine is combined with Valproic Acid.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Morphine.Approved, Investigational
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Morphine.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Morphine.Approved
VenlafaxineThe metabolism of Morphine can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Morphine can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Morphine is combined with Vigabatrin.Approved
VinblastineThe serum concentration of Morphine can be decreased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Morphine.Approved, Investigational
VincristineThe serum concentration of Morphine can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Morphine can be increased when it is combined with Vinorelbine.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Morphine.Approved
VoriconazoleThe metabolism of Morphine can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Morphine is combined with Vortioxetine.Approved
XylazineThe risk or severity of adverse effects can be increased when Morphine is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Morphine is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Morphine is combined with Ziconotide.Approved
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Morphine.Approved
ZimelidineThe serum concentration of Morphine can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Morphine can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Morphine is combined with Zolazepam.Vet Approved
ZolpidemMorphine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Morphine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Morphine is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Morphine is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Morphine is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Take with food.
  • To avoid constipation: increase your daily intake of fiber (beans, whole grains, vegetables).
References
Synthesis Reference

Nagaraj R. Ayyangar, Anil R. Choudhary, Uttam R. Kalkote, Vasant K. Sharma, “Process for the preparation of codeine from morphine.” U.S. Patent US4764615, issued May, 1912.

US4764615
General References
  1. Kilpatrick GJ, Smith TW: Morphine-6-glucuronide: actions and mechanisms. Med Res Rev. 2005 Sep;25(5):521-44. [PubMed:15952175 ]
  2. Loguinov AV, Anderson LM, Crosby GJ, Yukhananov RY: Gene expression following acute morphine administration. Physiol Genomics. 2001 Aug 28;6(3):169-81. [PubMed:11526201 ]
External Links
ATC CodesA07DA52N02AA51N02AA01N02AG01
AHFS Codes
  • 28:08.08
  • 84:24.12
PDB EntriesNot Available
FDA labelDownload (1.2 MB)
MSDSDownload (51.7 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9971
Blood Brain Barrier+0.9882
Caco-2 permeable+0.8867
P-glycoprotein substrateSubstrate0.8787
P-glycoprotein inhibitor INon-inhibitor0.8782
P-glycoprotein inhibitor IINon-inhibitor0.956
Renal organic cation transporterInhibitor0.6221
CYP450 2C9 substrateNon-substrate0.7451
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateSubstrate0.7375
CYP450 1A2 substrateNon-inhibitor0.5191
CYP450 2C9 inhibitorNon-inhibitor0.9046
CYP450 2D6 inhibitorNon-inhibitor0.647
CYP450 2C19 inhibitorNon-inhibitor0.8155
CYP450 3A4 inhibitorNon-inhibitor0.9176
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7503
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.9634
BiodegradationNot ready biodegradable0.9944
Rat acute toxicity2.8989 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8367
hERG inhibition (predictor II)Non-inhibitor0.874
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • King pharmaceuticals inc
  • Actavis elizabeth llc
  • Ekr therapeutics inc
  • App pharmaceuticals llc
  • Baxter healthcare corp anesthesia and critical care
  • Hospira inc
  • Mallinckrodt chemical inc
  • Meridian medical technologies inc
  • Watson laboratories inc
  • Roxane laboratories inc
  • Clonmel healthcare ltd
  • Endo pharmaceuticals inc
  • Kv pharmaceutical co
  • Mallinckrodt inc
  • Purdue pharma lp
  • Xanodyne pharmaceutics inc
  • Actavis
Packagers
Dosage forms
FormRouteStrength
Capsule, coated, extended releaseOral60 mg/1
Capsule, extended releaseOral120 mg/1
Capsule, extended releaseOral45 mg/1
Capsule, extended releaseOral75 mg/1
Capsule, extended releaseOral90 mg/1
InjectionEpidural; Intrathecal; Intravenous.5 mg/mL
InjectionEpidural; Intrathecal; Intravenous1 mg/mL
Capsule, extended releaseOral
Injection, solutionEpidural; Intrathecal10 mg/mL
Injection, solutionEpidural; Intrathecal25 mg/mL
Capsule, extended releaseOral130 mg/1
Capsule, extended releaseOral150 mg/1
Capsule, extended releaseOral40 mg/1
Capsule, extended releaseOral50 mg
Capsule, extended releaseOral70 mg/1
CapsuleOral20 mg/1
Capsule, extended releaseOral10 mg
Capsule, extended releaseOral100 mg
Capsule, extended releaseOral15 mg
Capsule, extended releaseOral200 mg
Capsule, extended releaseOral30 mg
Capsule, extended releaseOral60 mg
CapsuleOral10 mg
CapsuleOral20 mg
CapsuleOral30 mg
CapsuleOral5 mg
TabletOral40 mg
SyrupOral50 mg
TabletOral60 mg
SolutionIntramuscular; Intravenous; Subcutaneous50 mg
SolutionIntramuscular; Intravenous; Subcutaneous25 mg
SolutionEpidural; Intravenous; Subcutaneous0.5 mg
SolutionEpidural; Intravenous; Subcutaneous1 mg
Capsule, extended releaseOral10 mg/1
Capsule, extended releaseOral100 mg/1
Capsule, extended releaseOral20 mg/1
Capsule, extended releaseOral200 mg/1
Capsule, extended releaseOral30 mg/1
Capsule, extended releaseOral50 mg/1
Capsule, extended releaseOral60 mg/1
Capsule, extended releaseOral80 mg/1
InjectionIntramuscular10 mg/.7mL
InjectionIntramuscular; Intravenous; Subcutaneous10 mg/mL
InjectionIntramuscular; Intravenous; Subcutaneous15 mg/mL
InjectionIntramuscular; Intravenous; Subcutaneous5 mg/mL
InjectionIntramuscular; Intravenous; Subcutaneous8 mg/mL
InjectionIntravenous1 mg/mL
InjectionIntravenous10 mg/mL
InjectionIntravenous4 mg/mL
InjectionIntravenous8 mg/mL
Injection, solutionEpidural; Intramuscular; Intrathecal; Intravenous2 mg/mL
Injection, solutionEpidural; Intrathecal; Intravenous.5 mg/mL
Injection, solutionEpidural; Intrathecal; Intravenous1 mg/mL
Injection, solutionIntramuscular; Intravenous10 mg/mL
Injection, solutionIntramuscular; Intravenous2 mg/mL
Injection, solutionIntramuscular; Intravenous4 mg/mL
Injection, solutionIntramuscular; Intravenous5 mg/mL
Injection, solutionIntramuscular; Intravenous8 mg/mL
Injection, solutionIntrathecal; Intravenous.5 mg/mL
Injection, solutionIntravenous.5 mg/mL
Injection, solutionIntravenous1 mg/mL
Injection, solutionIntravenous10 mg/mL
Injection, solutionIntravenous15 mg/mL
Injection, solutionIntravenous2 mg/mL
Injection, solutionIntravenous25 mg/mL
Injection, solutionIntravenous4 mg/mL
Injection, solutionIntravenous5 mg/mL
Injection, solutionIntravenous8 mg/mL
Injection, solutionIntravenous; Subcutaneous10 mg/10mL
Injection, solutionIntravenous; Subcutaneous30 mg/30mL
Injection, solution, concentrateIntravenous25 mg/mL
Injection, solution, concentrateIntravenous50 mg/mL
SolutionOral10 mg/5mL
SolutionOral100 mg/5mL
SolutionOral20 mg/5mL
SolutionOral20 mg/mL
Solution, concentrateOral100 mg/5mL
SuppositoryRectal10 mg/1
SuppositoryRectal20 mg/1
SuppositoryRectal30 mg/1
SuppositoryRectal5 mg/1
TabletOral15 mg/1
TabletOral30 mg/1
Tablet, extended releaseOral100 mg/1
Tablet, extended releaseOral200 mg/1
Tablet, extended releaseOral60 mg/1
Tablet, film coated, extended releaseOral100 mg/1
Tablet, film coated, extended releaseOral15 mg/1
Tablet, film coated, extended releaseOral200 mg/1
Tablet, film coated, extended releaseOral30 mg/1
Tablet, film coated, extended releaseOral60 mg/1
TabletOral60 mg/1
TabletOral100 mg/1
TabletOral200 mg/1
Tablet, extended releaseOral15 mg/1
Tablet, extended releaseOral30 mg/1
LiquidIntramuscular; Intravenous; Subcutaneous10 mg
LiquidIntramuscular; Intravenous; Subcutaneous15 mg
SolutionIntravenous; Subcutaneous1 mg
SolutionIntravenous; Subcutaneous2 mg
SolutionIntravenous; Subcutaneous5 mg
SolutionIntramuscular; Intravenous; Subcutaneous10 mg
SolutionIntramuscular; Intravenous; Subcutaneous15 mg
SolutionIntravenous1 mg
SolutionIntramuscular; Intravenous; Subcutaneous2 mg
SolutionIntravenous5 mg
SolutionIntramuscular; Intravenous; Subcutaneous1 mg
LiquidIntramuscular; Intravenous; Subcutaneous2 mg
LiquidIntravenous; Subcutaneous1 mg
LiquidIntravenous; Subcutaneous2 mg
LiquidIntramuscular; Intravenous; Subcutaneous50 mg
LiquidIntramuscular; Intravenous; Subcutaneous25 mg
LiquidIntravenous25 mg
LiquidIntravenous50 mg
LiquidIntravenous1.1 mg
SolutionEpidural0.5 mg
SolutionEpidural1 mg
Tablet, extended releaseOral100 mg
Tablet, extended releaseOral15 mg
Tablet, extended releaseOral200 mg
Tablet, extended releaseOral30 mg
Tablet, extended releaseOral60 mg
Suppository, extended releaseRectal30 mg
Suppository, extended releaseRectal100 mg
Suppository, extended releaseRectal200 mg
Suppository, extended releaseRectal60 mg
Tablet, extended releaseOral5 mg
Capsule, extended releaseOral120 mg
Capsule, extended releaseOral150 mg
Capsule, extended releaseOral90 mg
SuppositoryRectal10 mg
TabletOral10 mg
TabletOral20 mg
TabletOral30 mg
TabletOral5 mg
LiquidOral2 mg/5mL
TinctureOral10 mg
SolutionOral1 g/100mL
SolutionOral10 mg/mL
TinctureOral10 mg/mL
SyrupOral20 mg
Solution / dropsOral50 mg
Solution / dropsOral20 mg
SuppositoryRectal20 mg
SuppositoryRectal30 mg
SuppositoryRectal5 mg
SyrupOral10 mg
SyrupOral1 mg
SyrupOral5 mg
TabletOral25 mg
TabletOral50 mg
Capsule, extended releaseOral20 mg
Capsule, extended releaseOral40 mg
Prices
Unit descriptionCostUnit
Depodur 15 mg/1.5 ml vial618.18USD ml
Roxanol 20 mg/ml Solution 120ml Bottle95.98USD bottle
Morphine Sulfate 20 mg/5ml Solution 500ml Bottle65.05USD bottle
Apokyn 30 mg/3 ml cartridge52.48USD ml
Morphine Sulfate 10 mg/5ml Solution 500ml Bottle38.55USD bottle
Kadian er 200 mg capsule35.43USD capsule
Kadian er 100 mg capsule23.01USD capsule
Roxanol 20 mg/ml Solution 30ml Bottle22.99USD bottle
Morphine Sulfate 10 mg/5ml Solution 100ml Bottle21.99USD bottle
Oramorph sr 60 mg tablet21.76USD tablet
Ms contin 200 mg tablet21.5USD tablet
Kadian er 80 mg capsule18.66USD capsule
Roxanol 20 mg/ml Solution 240ml Bottle17.99USD bottle
Avinza 90 mg capsule17.56USD capsule
Oramorph sr 100 mg tablet17.16USD tablet
Kadian 100 mg 24 Hour Capsule16.93USD capsule
MS Contin 200 mg 12 Hour tablet16.32USD tablet
Kadian 100 mg capsule sr16.25USD capsule
Kadian er 60 mg capsule14.31USD capsule
AVINza 90 mg 24 Hour Capsule13.21USD capsule
Kadian 80 mg capsule sr12.96USD capsule
Avinza 120 mg capsule12.07USD capsule
Kadian er 50 mg capsule11.76USD capsule
Ms contin 100 mg tablet11.75USD tablet
Avinza 60 mg capsule11.58USD capsule
AVINza 120 mg 24 Hour Capsule11.33USD capsule
Avinza 75 mg capsule10.79USD capsule
Morphine sulfate powder10.61USD g
Avinza 45 mg capsule10.22USD capsule
Kadian 60 mg 24 Hour Capsule9.06USD capsule
Morphine Sulfate CR 200 mg 12 Hour tablet8.97USD tablet
MS Contin 100 mg 12 Hour tablet8.89USD tablet
Morphine sulf 30 mg suppository8.44USD suppository
AVINza 60 mg 24 Hour Capsule8.36USD capsule
Ms contin 60 mg tablet7.95USD tablet
Infumorph 10 mg/ml ampul p-f7.8USD ml
Kadian 50 mg 24 Hour Capsule7.71USD capsule
Kadian er 30 mg capsule7.13USD capsule
Oramorph sr 30 mg tablet6.83USD tablet
Morphine sulf 20 mg suppository6.71USD suppository
Kadian er 10 mg capsule6.35USD capsule
Morphine sulf 10 mg suppository6.25USD suppository
Avinza 30 mg capsule6.0USD capsule
MS Contin 60 mg 12 Hour tablet5.71USD tablet
Kadian er 20 mg capsule5.69USD capsule
Ms Contin 200 mg Sustained-Release Tablet5.62USD tablet
Kadian 30 mg 24 Hour Capsule4.8USD capsule
Kadian 20 mg 24 Hour Capsule4.76USD capsule
AVINza 30 mg 24 Hour Capsule4.47USD capsule
Morphine sulf 5 mg suppository4.45USD suppository
Morphine Sulfate CR 100 mg 12 Hour tablet4.33USD tablet
M-Eslon 200 mg Extended-Release Capsule4.3USD capsule
Oramorph sr 15 mg tablet4.12USD tablet
Ms contin cr 30 mg tablet4.09USD tablet
Kadian 10 mg capsule sr4.05USD capsule
Morphine Hp 50 50 mg/ml4.01USD ml
Kadian 10 mg 24 Hour Capsule4.0USD capsule
Ms contin 15 mg tablet3.58USD tablet
MS Contin 30 mg 12 Hour tablet3.26USD tablet
Novo-Morphine Sr 200 mg Sustained-Release Tablet3.09USD tablet
Pms-Morphine Sulfate Sr 200 mg Sustained-Release Tablet3.09USD tablet
Ms Contin 100 mg Sustained-Release Tablet3.02USD tablet
Morphine Sulfate CR 60 mg 12 Hour tablet3.0USD tablet
Morphine Hp 25 25 mg/ml2.9USD ml
Statex 30 mg Suppository2.55USD suppository
Kadian 100 mg Sustained-Release Capsule2.35USD capsule
Statex 20 mg Suppository2.32USD suppository
Morphine Lp Epidural 1 mg/ml2.24USD ml
M-Eslon 100 mg Extended-Release Capsule2.15USD capsule
MS Contin 15 mg 12 Hour tablet2.13USD tablet
Ms Contin 60 mg Sustained-Release Tablet1.98USD tablet
Statex 10 mg Suppository1.95USD suppository
Morph sulf 5 mg/0.25 ml vial1.83USD vial
Statex 5 mg Suppository1.75USD suppository
Novo-Morphine Sr 100 mg Sustained-Release Tablet1.66USD tablet
Pms-Morphine Sulfate Sr 100 mg Sustained-Release Tablet1.66USD tablet
Morphine Sulfate CR 30 mg 12 Hour tablet1.63USD tablet
Morphine 8 mg/ml ampule1.56USD ml
Kadian 50 mg Sustained-Release Capsule1.35USD capsule
Duramorph 0.5 mg/ml ampul1.31USD ml
Astramorph-pf 1 mg/ml ampul1.15USD ml
Ms Contin 30 mg Sustained-Release Tablet1.13USD tablet
Morphine Lp Epidural 0.5 mg/ml1.12USD ml
Morphine Sulfate 15 mg/ml1.03USD ml
Morphine Sulfate 10 mg/ml1.02USD ml
Novo-Morphine Sr 60 mg Sustained-Release Tablet1.01USD tablet
Pms-Morphine Sulfate Sr 60 mg Sustained-Release Tablet1.01USD tablet
Ratio-Morphine Sulfate Sr 60 mg Sustained-Release Tablet1.01USD tablet
M-Eslon 60 mg Extended-Release Capsule1.0USD capsule
Statex 50 mg/ml Drops0.99USD ml
Morphine Sulfate CR 15 mg 12 Hour tablet0.93USD tablet
Duramorph 1 mg/ml ampul0.91USD ml
M.O.S.-Sr 60 mg Sustained-Release Tablet0.89USD tablet
Morphine 50 mg/25 ml-d5w syr0.86USD ml
Morphine-ns 10 mg/ml syringe0.86USD ml
Morphine-ns 5 mg/ml syringe0.8USD ml
Ms Contin 15 mg Sustained-Release Tablet0.75USD tablet
Morphine 5 mg/ml vial0.74USD ml
Kadian 20 mg Sustained-Release Capsule0.73USD capsule
Astramorph-pf 0.5 mg/ml amp0.72USD ml
Morphine Sulfate 15 mg tablet0.65USD tablet
Morphine Sulfate 30 mg tablet0.65USD tablet
Morphine 1 mg/ml vial p-f0.6USD ml
Morphine-ns 1 mg/ml syringe0.58USD ml
Novo-Morphine Sr 30 mg Sustained-Release Tablet0.57USD tablet
Pms-Morphine Sulfate Sr 30 mg Sustained-Release Tablet0.57USD tablet
Ratio-Morphine Sulfate Sr 30 mg Sustained-Release Tablet0.57USD tablet
M-Eslon 30 mg Extended-Release Capsule0.56USD capsule
Morphine 0.5 mg/ml vial0.55USD ml
Morphine sulfate 50 mg/ml vial0.55USD ml
Morphine sulfate ir 30 mg tablet0.55USD tablet
Ratio-Morphine 20 mg/ml Syrup0.55USD syrup
Statex 20 mg/ml Drops0.52USD ml
M.O.S.-Sr 30 mg Sustained-Release Tablet0.51USD tablet
Morphine 1 mg/ml syringe0.48USD ml
Morphine 10 mg/ml vial0.48USD ml
Ms.Ir 30 mg Tablet0.48USD tablet
Morphine sulfate 25 mg/ml vial0.43USD ml
Morphine sulf 1 mg/ml vial0.4USD ml
M.O.S. Sulfate 50 mg Tablet0.39USD tablet
Statex 50 mg Tablet0.39USD tablet
Kadian 10 mg Sustained-Release Capsule0.38USD capsule
M-Eslon 15 mg Extended-Release Capsule0.38USD capsule
Ms.Ir 20 mg Tablet0.38USD tablet
Novo-Morphine Sr 15 mg Sustained-Release Tablet0.37USD tablet
Pms-Morphine Sulfate Sr 15 mg Sustained-Release Tablet0.37USD tablet
Ratio-Morphine Sulfate Sr 15 mg Sustained-Release Tablet0.37USD tablet
M-Eslon 10 mg Extended-Release Capsule0.33USD capsule
Morphine sulfate ir 15 mg tablet0.32USD tablet
Morphine 15 mg/ml vial0.3USD ml
Morphine-ns 25 mg/25 ml syr0.26USD ml
M.O.S. Sulfate 25 mg Tablet0.25USD tablet
Statex 25 mg Tablet0.25USD tablet
Ms.Ir 10 mg Tablet0.21USD tablet
Ratio-Morphine 10 mg/ml Syrup0.19USD syrup
M.O.S. Sulfate 10 mg Tablet0.19USD tablet
Statex 10 mg Tablet0.19USD tablet
Morphine-ns 5 mg/ml0.16USD ml
Morphine-ns 55 mg/55 ml syr0.14USD ml
Ms.Ir 5 mg Tablet0.14USD tablet
M.O.S. Sulfate 5 mg Tablet0.12USD tablet
Statex 5 mg Tablet0.12USD tablet
Morphine 1 mg/ml-d5w 100 ml0.1USD ml
Morphine-ns 150 mg/150 ml0.1USD ml
Statex 5 mg/ml Syrup0.08USD ml
Morphine 1 mg/ml-d5w 250 ml0.06USD ml
Ratio-Morphine 5 mg/ml Syrup0.05USD syrup
Ratio-Morphine 1 mg/ml Syrup0.02USD syrup
Statex 1 mg/ml Syrup0.02USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2065210 No2000-08-292012-04-06Canada
CA2128591 No1999-03-232014-07-21Canada
US5378474 No1993-03-232010-03-23Us
US5807572 No1995-09-152015-09-15Us
US5891467 No1997-01-312017-01-31Us
US5931809 No1995-07-142015-07-14Us
US5962016 No1997-01-312017-01-31Us
US5997899 No1996-09-012016-09-01Us
US6066339 No1997-11-252017-11-25Us
US6171613 No1996-10-012016-10-01Us
US6193998 No1996-09-012016-09-01Us
US6241999 No1996-09-012016-09-01Us
US7682633 No2007-06-192027-06-19Us
US7682634 No2007-06-192027-06-19Us
US7815934 No2007-12-122027-12-12Us
US7955619 No2008-08-122028-08-12Us
US8158156 No2007-06-192027-06-19Us
US8623418 No2009-11-072029-11-07Us
US8685443 No2005-07-032025-07-03Us
US8685444 No2005-07-032025-07-03Us
US8846104 No2007-06-192027-06-19Us
US8877247 No2007-06-192027-06-19Us
US9072781 No2014-03-122034-03-12Us
US9192608 No2014-03-122034-03-12Us
US9248229 No2014-03-122034-03-12Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point255 °CPhysProp
water solubility149 mg/L (at 20 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP0.89AVDEEF,A ET AL. (1996)
logS-3.28ADME Research, USCD
pKa8.21 (at 25 °C)LIDE,DR (1995)
Predicted Properties
PropertyValueSource
Water Solubility10.2 mg/mLALOGPS
logP0.99ALOGPS
logP0.9ChemAxon
logS-1.4ALOGPS
pKa (Strongest Acidic)10.26ChemAxon
pKa (Strongest Basic)9.12ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area52.93 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity80.12 m3·mol-1ChemAxon
Polarizability29.95 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (9.42 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as morphinans. These are polycyclic compounds with a four-ring skeleton with three condensed six-member rings forming a partially hydrogenated phenanthrene moiety, one of which is aromatic while the two others are alicyclic.
KingdomOrganic compounds
Super ClassAlkaloids and derivatives
ClassMorphinans
Sub ClassNot Available
Direct ParentMorphinans
Alternative Parents
Substituents
  • Morphinan
  • Benzylisoquinoline
  • Phenanthrene
  • Tetralin
  • Benzofuran
  • Aralkylamine
  • Alkyl aryl ether
  • Benzenoid
  • Piperidine
  • Tertiary aliphatic amine
  • Tertiary amine
  • Secondary alcohol
  • Oxacycle
  • Azacycle
  • Organoheterocyclic compound
  • Ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Voltage-gated calcium channel activity
Specific Function:
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone. Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G-protein complex and subsequent exchange of GDP for GTP in the G-protein alpha subunit leading to dissociati...
Gene Name:
OPRM1
Uniprot ID:
P35372
Molecular Weight:
44778.855 Da
References
  1. Yamada H, Shimoyama N, Sora I, Uhl GR, Fukuda Y, Moriya H, Shimoyama M: Morphine can produce analgesia via spinal kappa opioid receptors in the absence of mu opioid receptors. Brain Res. 2006 Apr 14;1083(1):61-9. Epub 2006 Mar 10. [PubMed:16530171 ]
  2. Choi HS, Kim CS, Hwang CK, Song KY, Wang W, Qiu Y, Law PY, Wei LN, Loh HH: The opioid ligand binding of human mu-opioid receptor is modulated by novel splice variants of the receptor. Biochem Biophys Res Commun. 2006 May 19;343(4):1132-40. Epub 2006 Mar 23. [PubMed:16580639 ]
  3. Castro RR, Cunha FQ, Silva FS Jr, Rocha FA: A quantitative approach to measure joint pain in experimental osteoarthritis--evidence of a role for nitric oxide. Osteoarthritis Cartilage. 2006 Aug;14(8):769-76. Epub 2006 Mar 31. [PubMed:16580848 ]
  4. Johnson EA, Oldfield S, Braksator E, Gonzalez-Cuello A, Couch D, Hall KJ, Mundell SJ, Bailey CP, Kelly E, Henderson G: Agonist-selective mechanisms of mu-opioid receptor desensitization in human embryonic kidney 293 cells. Mol Pharmacol. 2006 Aug;70(2):676-85. Epub 2006 May 8. [PubMed:16682505 ]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  6. doi:10.1021/cn9000236 [Link]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synthetic opioids and for the psychoactive diterpene salvinorin A. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates th...
Gene Name:
OPRK1
Uniprot ID:
P41145
Molecular Weight:
42644.665 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Leventhal L, Silva RM, Rossi GC, Pasternak GW, Bodnar RJ: Morphine-6beta-glucuronide-induced hyperphagia: characterization of opioid action by selective antagonists and antisense mapping in rats. J Pharmacol Exp Ther. 1998 Nov;287(2):538-44. [PubMed:9808678 ]
  4. Kozak CA, Filie J, Adamson MC, Chen Y, Yu L: Murine chromosomal location of the mu and kappa opioid receptor genes. Genomics. 1994 Jun;21(3):659-61. [PubMed:7959748 ]
  5. Teodorov E, Modena CC, Sukikara MH, Felicio LF: Preliminary study of the effects of morphine treatment on opioid receptor gene expression in brain structures of the female rat. Neuroscience. 2006 Sep 1;141(3):1225-31. Epub 2006 Jun 6. [PubMed:16753266 ]
  6. doi:10.1021/cn9000236 [Link]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurot...
Gene Name:
OPRD1
Uniprot ID:
P41143
Molecular Weight:
40368.235 Da
References
  1. Yamada H, Shimoyama N, Sora I, Uhl GR, Fukuda Y, Moriya H, Shimoyama M: Morphine can produce analgesia via spinal kappa opioid receptors in the absence of mu opioid receptors. Brain Res. 2006 Apr 14;1083(1):61-9. Epub 2006 Mar 10. [PubMed:16530171 ]
  2. Dortch-Carnes J, Russell KR: Morphine-induced reduction of intraocular pressure and pupil diameter: role of nitric oxide. Pharmacology. 2006;77(1):17-24. Epub 2006 Mar 13. [PubMed:16534251 ]
  3. Koch T, Wu DF, Yang LQ, Brandenburg LO, Hollt V: Role of phospholipase D2 in the agonist-induced and constitutive endocytosis of G-protein coupled receptors. J Neurochem. 2006 Apr;97(2):365-72. Epub 2006 Mar 15. [PubMed:16539674 ]
  4. Galeotti N, Stefano GB, Guarna M, Bianchi E, Ghelardini C: Signaling pathway of morphine induced acute thermal hyperalgesia in mice. Pain. 2006 Aug;123(3):294-305. Epub 2006 May 2. [PubMed:16650582 ]
  5. Asensio VJ, Miralles A, Garcia-Sevilla JA: Stimulation of mitogen-activated protein kinase kinases (MEK1/2) by mu-, delta- and kappa-opioid receptor agonists in the rat brain: regulation by chronic morphine and opioid withdrawal. Eur J Pharmacol. 2006 Jun 6;539(1-2):49-56. Epub 2006 Apr 6. [PubMed:16678156 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  7. Kieffer BL, Gaveriaux-Ruff C: Exploring the opioid system by gene knockout. Prog Neurobiol. 2002 Apr;66(5):285-306. [PubMed:12015197 ]
  8. doi:10.1021/cn9000236 [Link]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Glucuronosyltransferase activity
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds.Its unique specificity for 3,4-catechol estrogens and estriol suggests it may play an important role in regulating the level and activity of these potent and active estrogen metabolites. Is also active with androsterone, hyodeoxycholic acid and tetrachlorocatechol...
Gene Name:
UGT2B7
Uniprot ID:
P16662
Molecular Weight:
60694.12 Da
References
  1. Coffman BL, Rios GR, King CD, Tephly TR: Human UGT2B7 catalyzes morphine glucuronidation. Drug Metab Dispos. 1997 Jan;25(1):1-4. [PubMed:9010622 ]
  2. Takeda S, Ishii Y, Iwanaga M, Mackenzie PI, Nagata K, Yamazoe Y, Oguri K, Yamada H: Modulation of UDP-glucuronosyltransferase function by cytochrome P450: evidence for the alteration of UGT2B7-catalyzed glucuronidation of morphine by CYP3A4. Mol Pharmacol. 2005 Mar;67(3):665-72. Epub 2004 Dec 20. [PubMed:15611481 ]
  3. Yamada H, Ishii K, Ishii Y, Ieiri I, Nishio S, Morioka T, Oguri K: Formation of highly analgesic morphine-6-glucuronide following physiologic concentration of morphine in human brain. J Toxicol Sci. 2003 Dec;28(5):395-401. [PubMed:14746343 ]
  4. Abildskov K, Weldy P, Garland M: Molecular cloning of the baboon UDP-glucuronosyltransferase 2B gene family and their activity in conjugating morphine. Drug Metab Dispos. 2010 Apr;38(4):545-53. doi: 10.1124/dmd.109.030635. Epub 2010 Jan 13. [PubMed:20071451 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the IX-alpha-C8 and IX-alpha-C12 monoconjugates and diconjugate. Is also able to catalyze the glucuronidation of 17beta-estradiol, 17alpha-ethinylestradiol, 1-hydroxypyrene, 4-methylumbelliferone, 1-naph...
Gene Name:
UGT1A1
Uniprot ID:
P22309
Molecular Weight:
59590.91 Da
References
  1. Ohno S, Kawana K, Nakajin S: Contribution of UDP-glucuronosyltransferase 1A1 and 1A8 to morphine-6-glucuronidation and its kinetic properties. Drug Metab Dispos. 2008 Apr;36(4):688-94. doi: 10.1124/dmd.107.019281. Epub 2008 Jan 10. [PubMed:18187562 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.
Gene Name:
UGT1A8
Uniprot ID:
Q9HAW9
Molecular Weight:
59741.035 Da
References
  1. Ohno S, Kawana K, Nakajin S: Contribution of UDP-glucuronosyltransferase 1A1 and 1A8 to morphine-6-glucuronidation and its kinetic properties. Drug Metab Dispos. 2008 Apr;36(4):688-94. doi: 10.1124/dmd.107.019281. Epub 2008 Jan 10. [PubMed:18187562 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Glucuronosyltransferase activity
Specific Function:
UDPGTs are of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isozyme displays activity toward several classes of xenobiotic substrates, including simple phenolic compounds, 7-hydroxylated coumarins, flavonoids, anthraquinones, and certain drugs and their hydroxylated metabolites. It also catalyzes the glucuronidatio...
Gene Name:
UGT2B15
Uniprot ID:
P54855
Molecular Weight:
61035.815 Da
References
  1. Abildskov K, Weldy P, Garland M: Molecular cloning of the baboon UDP-glucuronosyltransferase 2B gene family and their activity in conjugating morphine. Drug Metab Dispos. 2010 Apr;38(4):545-53. doi: 10.1124/dmd.109.030635. Epub 2010 Jan 13. [PubMed:20071451 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Glucuronosyltransferase activity
Specific Function:
UDPGTs are of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isozyme is active on polyhydroxylated estrogens (such as estriol, 4-hydroxyestrone and 2-hydroxyestriol) and xenobiotics (such as 4-methylumbelliferone, 1-naphthol, 4-nitrophenol, 2-aminophenol, 4-hydroxybiphenyl and menthol). It is capable of 6 alpha-hydr...
Gene Name:
UGT2B4
Uniprot ID:
P06133
Molecular Weight:
60512.035 Da
References
  1. Abildskov K, Weldy P, Garland M: Molecular cloning of the baboon UDP-glucuronosyltransferase 2B gene family and their activity in conjugating morphine. Drug Metab Dispos. 2010 Apr;38(4):545-53. doi: 10.1124/dmd.109.030635. Epub 2010 Jan 13. [PubMed:20071451 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Retinoic acid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.
Gene Name:
UGT1A3
Uniprot ID:
P35503
Molecular Weight:
60337.835 Da
References
  1. Green MD, King CD, Mojarrabi B, Mackenzie PI, Tephly TR: Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP-glucuronosyltransferase 1A3. Drug Metab Dispos. 1998 Jun;26(6):507-12. [PubMed:9616184 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25. [PubMed:12699389 ]
  2. Troutman MD, Thakker DR: Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res. 2003 Aug;20(8):1210-24. [PubMed:12948019 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 09, 2016 03:14